



Reasons for excluding studies on patient-reported outcomes in a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004720
Article Type:	Research
Date Submitted by the Author:	19-Dec-2013
Complete List of Authors:	Peinemann, Frank; Children's Hospital, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany, Labeit, Alexander; University of Illinois, Outcomes Research Center Thielscher, Christian; FOM University of Applied Science for Economics & Management, Pinkawa, Michael; University Hospital, Department of Radiotherapy
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Urology, Patient-centred medicine, Evidence based practice
Keywords:	Adult surgery < SURGERY, Radiation oncology < RADIOTHERAPY, Urological tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1 *Subject: Reasons for excluding PRO studies*

2
3
4 Reasons for excluding studies on patient-reported outcomes in a systematic review

5
6
7 Frank Peinemann,^{1,*} Alexander Michael Labeit,^{2,3} Christian Thielscher,⁴ Michael Pinkawa,⁵

8
9
10 ¹Children's Hospital, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

11 ²Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty

12
13 Mannheim of the University of Heidelberg, Maybachstr. 14, 68169 Mannheim, Germany

14 ³Outcomes Research Center, University of Illinois, One Illini Drive, Peoria, IL 61656, USA

15 ⁴FOM University of Applied Science for Economics & Management, Leimkugelstr. 6, 45141
16
17 Essen, Germany

18
19 ⁵Department of Radiotherapy, University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany

20
21
22 FP: pubmedprjournal@gmail.com

23
24 AML: alexander.labeit@yahoo.de

25
26 CT: christian.thielscher@fom.de

27
28 MP: mpinkawa@ukaachen.de

29
30
31
32
33
34 *Corresponding author: Frank Peinemann, M.D., M.Sc., Children's Hospital, University of
35 Cologne, Kerpener Str. 62, 50937 Cologne, Germany; e-mail: pubmedprjournal@gmail.com.
36
37 Phone: +49-176-31130745.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2

3

4 **Abstract**

5

6

7 Background

8

9

10 Within the frame of a systematic review, we evaluated patient-reported outcomes of perma-

11

12 nent interstitial low-dose rate brachytherapy in patients with localized prostate cancer.

13

14

15 Objective

16

17

18 To summarize qualitatively the reasons for exclusion of nonrandomized controlled trials re-

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

reporting patient-reported outcomes.

Methods

We searched PubMed, MEDLINE, EMBASE, and The Cochrane Library without restrictions on 14 June 2010. We defined the inclusion criteria according to the PICO framework. The outcomes in the present publication concerned methodological issues and were different from the initial publication: fulfilment of basic inclusion criteria according to a PICO framework and accomplishment of requirements to contain high risk of bias.

Results

We found that 21 of 50 excluded nonrandomized controlled trials did not meet PICO inclusion criteria. The rest of 29 of 50 studies lacked quality of reporting. The resulting flaws included attrition bias due to loss of follow-up, lack of reporting baseline data, potential confounding due to unadjusted data, and lack of statistical comparison between groups.

Conclusion

1 *Subject: Reasons for excluding PRO studies*

2
3 With respect to the reporting of patient-reported outcomes, active efforts are required to im-
4
5 prove the quality of reporting in nonrandomized controlled trials concerning permanent inter-
6
7 stitial low-dose rate brachytherapy in patients with localized prostate cancer.
8
9

10
11
12
13
14
15
16
17 Key words: systematic review, patient-reported outcome, risk of bias
18
19
20
21
22
23
24
25

26 **Strengths and limitations of this study**

- 27
- 28
- 29
- 30 • We conducted a comprehensive literature search and strictly adhered to the projected
31 methodology.
- 32
- 33
- 34 • We identified a lack of quality in patient-reported studies, analysed the cause, and
35 suggested possible improvements in designing studies in the future.
- 36
- 37
- 38 • The systematic review is confined to a single disease and conclusions drawn from its
39 results may not be generalizable to other diseases.
- 40
- 41
- 42
- 43 • The limits for the inclusion of studies are arbitrarily set.
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 *Subject: Reasons for excluding PRO studies*

2 **Introduction**

3
4
5
6
7 We have conducted a systematic review to evaluate the effectiveness and adverse events of
8
9 permanent interstitial low-dose rate brachytherapy (LDR-BT) in patients with localized
10
11 prostate cancer categorized T1 to T2 [1]. We have compared LDR-BT with radical
12
13 prostatectomy (RP), external beam radiotherapy (EBRT), and 'no primary therapy' (NPT). We
14
15 used the term NPT to accommodate different types of observation including active
16
17 surveillance, watchful waiting, and observing without a distinctive management. We have
18
19 included one randomized controlled trial (RCT) and 30 nonrandomized controlled trials
20
21 (NRCT). The primary outcome was overall survival and cancer-specific survival. The
22
23 secondary outcomes were clinically defined disease-free survival, biochemical recurrence-free
24
25 survival, physician-reported severe adverse events, and patient-reported outcomes such as
26
27 function and bother scores as well as generic and disease-related health-related quality of life.
28
29 We concluded that the current evidence is insufficient to allow a definitive conclusion about
30
31 overall survival. RP and EBRT can severely affect the structural integrity of neighboring
32
33 organs and their functions and can cause considerable long-term impairment of health-related
34
35 quality of life. In a view of expecting similar survival but a tremendous difference of adverse
36
37 events between treatment alternatives, valid data on health-related quality of life could tip the
38
39 balance. At least, we assume that shared-decision making and consideration of patients'
40
41 preferences in searching for the best individual treatment would rely on information on
42
43 health-related quality of life data. Of the 30 included nonrandomized studies, 13 studies
44
45 reported patient-reported outcomes (PRO) [2]. During the study selection process, we
46
47 experienced that we excluded another 50 nonrandomized PRO studies. We found it a pity that
48
49 we could not use the many data. We had the impression that a considerable number of studies
50
51 were excluded because of lack in reporting quality. Therefore, we wanted to summarize the
52
53 reasons for excluding those PRO studies and make aware that authors of PRO studies should
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2
3 meet some basic requirements for reporting of comparative PRO data to achieve higher
4
5 acceptance in the scientific community. The importance of reporting PRO has been addressed
6
7 by CONSORT [3] that recently has published a PRO extension to their acclaimed previous
8
9 statement with respect to RCT [4]. It may be wise to build a PRO extension to STROBE [5]
10
11 also to deal with the specific problems of observational studies.
12

13
14
15 The first aim of this study is to assess whether the excluded studies met the basic inclusion
16
17 criteria using the PICO framework. The second aim of this study is to whether the excluded
18
19 studies met requirements to contain high risk of bias.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2 **Materials and Methods**

3
4
5
6
7 While preparing this systematic review, we endorsed the PRISMA statement, adhered to its
8 principles and conformed to its checklist [6].

9 **Study inclusion criteria**

10
11
12 We defined the inclusion criteria according to the PICO framework that should include four
13 essential constituents, that is, the type of participants (P), intervention (I), comparator (C), and
14 outcome (O) [7]. The four PICO items can be supplemented by timing (T) and setting (S), two
15 other important features of a systematic review, to create the so-called PICOTS typology [8].
16
17 A further extension embraces the study design (SD) to complete all major items of a search
18 strategy (PICOTS-SD) [9].
19
20
21
22
23
24
25
26
27
28

29 *Population*

30
31
32 Initial and present publication: Localized prostate cancer is defined by the categories T1 to T2
33 of the Tumor-Node-Metastasis (TNM) staging system [10] if combined with an absence of
34 both regional lymph node metastasis (N0) and distant metastasis (M0).
35
36
37
38
39

40 *Intervention*

41
42
43 Initial and present publication: Brachytherapy [11] is short-distance radiotherapy placing
44 radiation sources with different duration and rates of dose delivery in or near tumors [12].
45
46 LDR-BT means implanting of low-energy radioactive sources emitting radiation, which are
47 contained in titanium pellets of the size of rice grains called seeds [13].
48
49
50
51
52

53 *Comparator*

54
55
56 Initial and present publication: The European Association of Urology (EAU) suggested 3
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2
3 different treatment concepts for localized prostate cancer in addition to LDR-BT [11]: Radical
4
5 prostatectomy (RP), external beam radiotherapy (EBRT), and different types of observation
6
7 including active surveillance, watchful waiting, and observing without a distinctive
8
9 management.
10

11
12 *Outcome*

13
14
15 Initial publication: Overall survival, cancer-specific survival, disease-free survival,
16
17 biochemical recurrence-free survival, severe adverse events, and patient-reported outcomes.
18
19 Patient-reported outcomes comprised function and bother scores as well as generic and
20
21 disease-related health-related quality of life.
22
23

24
25 Present publication: Fulfilment of basic inclusion criteria according to a PICO framework by
26
27 the excluded NRCT. Accomplishment of requirements to contain superimposed risk of bias in
28
29 addition to the high risk of bias caused by the lack of randomization framework by the
30
31 excluded NRCT.
32
33

34
35 *Timing*

36
37
38 Initial and present publication: We did not set limits on the length of the observation period.
39
40

41
42 *Setting*

43
44
45 Initial and present publication: We did not set limits on the setting such as type of country,
46
47 year of recruitment, or level of health care.
48
49

50
51 *Study design*

52
53
54 Initial publication: We included RCT and NRCT evaluating LDR-BT as monotherapy in pa-
55
56 tients with localized prostate cancer. The proportion of relevant patients was required to be at
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2
3 least 80% of the study population and the response rate of questionnaires was expected to be
4
5 at least 70%. For NRCT to be included, comparable baseline characteristics between treat-
6
7 ment groups or adjustment for imbalances of these data were required. Limits on year of pub-
8
9 lication or language were not applied.
10

11
12 Present publication: We included specifically the NRCT that were excluded in the initial
13
14 publication.
15

16 17 18 **Search strategy**

19
20 We searched PubMed, MEDLINE, EMBASE, and The Cochrane Library without restrictions
21
22 on study design, publication year, and language. We conducted the last database searches on
23
24 14 June 2010. We tailored the terms and syntax used for the search in MEDLINE via Ovid as
25
26 shown Table 1 to the requirements of the other databases.
27
28

29 30 31 **Study selection**

32
33 In the present study, we selected only those 50 nonrandomized studies on PRO that were ex-
34
35 cluded from the evaluation in the initial publication. In the study selection process, two re-
36
37 viewers independently judged whether a study was included or excluded. Differences were
38
39 resolved by discussion without the need for a third opinion.
40
41
42

43 44 45 **Data collection and analysis**

46
47 The reasons for exclusion were extracted independently by two reviewers. We sought for the
48
49 following data: the inclusion criteria using the PICO framework, the proportion of response of
50
51 participants to questionnaires, which was required to be at least 70%, the reporting of separate
52
53 baseline characteristics for each treatment group, the reporting of comparable baseline charac-
54
55 teristics or adjustment for imbalances of these data such as the use of a Cox proportional haz-
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2
3 ard model, and the reporting of statistics comparing treatment groups. Sufficient comparabil-
4
5 ity was defined as a difference between baseline values that were not statistically significant.
6
7 If a statistical test was not reported, we assumed two comparable values if the greater of the
8
9 two values was less than 10% above the smaller one. We also required that authors reported
10
11 effect measures and statistics testing the difference between treatment groups, for example, p-
12
13 values or effect measures including 95% confidence intervals. Reporting of within group
14
15 comparisons or before-and-after analyses were not deemed sufficient for inclusion. We did
16
17 not apply a principal summary measure as we aimed at synthesize the information in a quali-
18
19 tative way.
20
21

22 **Assessment of risk of bias and quality of reporting**

23
24
25 Two reviewers independently assessed the quality of reporting of NRCT according to the cri-
26
27 teria specified in the previous paragraph. We did not specifically assess the risk of bias be-
28
29 cause we decided to exclude all papers with regard to a lack of reporting essential data.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: Reasons for excluding PRO studies

Results

We documented the reasons for exclusion of all 50 nonrandomized studies that were identified as studies reporting on PRO (Table 2). In 42% (21 of 50) studies, simply the essential PICO framework was not met. In the majority of 58% (29 of 50) studies, the predefined requirement to apply measures to contain high risk of bias was not met. Of these 29 studies, 19 studies reported a proportion of patients responding to questionnaires of less than 70% or did not address this item. Baseline characteristics were not presented for treatment groups in 3 studies. In another 6 studies, baseline characteristics were not comparable between treatment groups or there was no confounder control in the analysis adjusting for important different factors such as mean age. The statistical comparison between treatment groups was deemed not appropriate in 1 study.

1 *Subject: Reasons for excluding PRO studies*

2 3 **Discussion**

4 5 6 **Main results**

7
8
9
10 In summary, we found that roughly 4 of 10 excluded PRO studies did not meet the essential
11 inclusion criteria using the PICO framework. This result is consistent with the problem of
12 information retrieval aiming at a high recall and ending up with a low precision. The papers
13 were obviously not relevant to the research question and we did not further examine the re-
14 porting quality. We also found that roughly 6 of 10 excluded PRO studies met the PICO
15 framework but did not provide predefined requirements to care sufficiently enough for a low
16 response of patients to questionnaires, for reporting baseline characteristics between treatment
17 groups, for adjusting differences in those baseline characteristics between treatment groups,
18 and to use appropriate statistics to compare the outcome between treatment groups.
19
20
21
22
23
24
25
26
27
28
29
30

31 **Quality of reporting of patient-reported outcomes**

32
33
34 We identified a lack of quality of reporting in many excluded NRCT and we want to stress the
35 importance of considering a series of requirements while conducting a study on PRO. Other
36 authors have reported recently that, concerning disease-specific mortality or disease-free sur-
37 vival, available studies did not show significant differences between treatment groups.
38 [14,15]. In view of unknown or small differences in survival measures, the results of patient-
39 reported outcomes studies could have a noticeable impact on medical decision making
40 [16,17]. None of the 50 excluded studies reported a non-responder analysis, though it is
41 known that non-responders may have different attitudes than responders. Etter 1997 conclud-
42 ed that low response rates may be associated with overestimating an effect and that the
43 strength and direction of a non-response bias may depend on the mechanism of non-response
44 [18]. Therefore, results may be confounded if the proportion of included data not available for
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2 analysis such as data from non-responders or due to loss to follow-up is considerable. We
3 believe that a value of 30% or more can be denoted as considerable. Lowering this threshold,
4 for example to 20%, would have resulted in less included studies. However, others suggested
5 that 20% or more loss would be sufficient for a high risk of bias threatening the validity of
6 results [19]. Concerning questionnaires, we recommend taking measures that are known to
7 improve response rates [20,21]. Edwards 2009 conducted a systematic review to identify ef-
8 fective strategies to increase the response to postal and electronic questionnaires [22]. The
9 authors found several strategies to increase the response, for example, pre-notification, fol-
10 low-up contact, shorter questionnaires, mentioning an obligation to respond, university spon-
11 sorship, non-monetary incentives, a statement that others had responded, an offer of survey
12 results, giving a deadline. We did not use a strict algorithm to differentiate between compara-
13 ble and not comparable baseline values between treatment groups. A statistically significant
14 difference was judged as not comparable. Not significant differences were also regarded as
15 not comparable if the difference was at least 10% of the lower of two values. Using this ap-
16 proach we tried to reduce subjective decisions. We are not aware of published strict algo-
17 rithms in this matter.

38 **High risk of bias inherent in nonrandomized controlled trials**

39 In the view of including only 1 RCT, the initial publication was based almost exclusively on
40 NRCT. However, the lack of randomization poses a very large challenge on the authors that
41 are advised to deal with essential problems such as selection bias and confounding. Other-
42 wise, the findings may not be valid and of limited usefulness and the many efforts may be in
43 vain. We want to stress that the nonrandomized design is associated with a high risk of bias
44 because known and unknown characteristics may be distributed unequally between groups
45 [23]. Certain study characteristics such as prospective design, concurrent control group,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2 adjustment of results with respect to different baseline values, and confounder control can
3 limit additional bias. For example, Ioannidis 2001 [24] reported that discrepancies between
4 RCT and NRCT were less common when only NRCT with a prospective design were
5 considered. The Cochrane Collaboration offers a guide for inclusion of nonrandomized
6 studies [25] and it has developed a tool for assessing the risk of bias in both RCT and
7 controlled NRS [26]. Guidelines for reporting observational studies have been published to
8 improve their quality [5]. Cox regression analysis, propensity-score-based analysis, and in-
9 strumental variable analysis are methods that have been used for correction of confounding
10 bias in non-randomized studies [27]. Different values of various outcome measures between
11 groups may be simply caused by different baseline data in lieu of absent significant treatment
12 effects. We accepted any type of method adjusting or stratifying for one or more known dif-
13 ferences in baseline characteristics. Nevertheless, it should be kept in mind that methods of
14 adjustment do not guarantee removal of bias and that residual confounding may remain high
15 [23]. Concerning the non-randomized design, we strongly recommend the use of methods for
16 adjusting the results for confounders to aim for a less biased estimation of the treatment effect
17 [28] and the adoption of guidelines for the reporting of observational studies [5].

39 **Strengths and limitations**

40 The strengths of the present study are a comprehensive literature search, strict adherence to
41 the projected methodology, the identification of lack of quality in PRO studies and addressing
42 the specific problems of PRO studies. We should consider some limitations: The study is con-
43 fined to a single disease and conclusions drawn from its results may not be generalizable to
44 other diseases. The arbitrary limits set for inclusion of studies are responsible for the extent of
45 excluded studies. These limits may be questioned by other investigators. During re-evaluation
46 of study quality, we found that one study fulfilled all criteria, although, this study was exclud-
47 ed.

1 *Subject: Reasons for excluding PRO studies*

2 ed in previous reports [29]. The minimum follow-up of 70% for inclusion was set arbitrarily
3 and others might find this threshold too low. We did not endorse the recently published re-
4 porting of PRO in randomized trials, an extension of the CONSORT statement [4]. All in-
5 cluded studies in the present review are nonrandomized. We think that the lack of randomiza-
6 tion is the prevailing issue. We did not endorse the CONSORT PRO extension for another
7 reason. The included studies were published many years before this extension was published.
8 There might be a need to develop an extension of the STROBE statement [5] aiming to im-
9 prove the reporting of PRO in nonrandomized studies. This extension could emphasize the
10 specific challenges of reporting PRO with respect to lack of randomization.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2 **Conclusions**

3
4
5
6
7 We found that a considerable number of non-randomized controlled reporting patient-reported
8
9 outcomes were excluded from a systematic review because of a lack of predefined reporting
10
11 requirements. The assumed overall risk of bias was regarded too high to consider the data of
12
13 these studies for inclusion in the systematic review. With respect to the reporting of patient-
14
15 reported outcomes, active efforts are required to improve the quality of reporting in nonran-
16
17 domized controlled trials and to increase the number of randomized controlled trials.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2

3

4

5

6

7 **Acknowledgements**

8

9

10 The authors declare that they have no competing interests. Parts of the study have been pre-
11 sented at 19th Cochrane Colloquium 19 to 22 October 2011 in Madrid, Spain. No funding
12 bodies had any role in study design, data collection and analysis, decision to publish, or prep-
13 aration of the manuscript.
14
15
16
17
18

19 **Contributorship Statement**

20

21

22 Frank Peinemann: design, data analysis, writing of the manuscript
23

24 Alexander Michael Labeit: interpretation of data
25

26 Christian Thielscher: interpretation of data
27

28 Michael Pinkawa: urological advice
29

30 **Data Sharing Statement**

31

32

33 No additional unpublished data
34

35 **Competing interests**

36

37

38 No additional unpublished data
39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Subject: Reasons for excluding PRO studies

References

1. Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M et al. Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer – a systematic review of randomized and non-randomized controlled clinical trials. *Eur Urol* 2011; 60(5): 881-893.
2. Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient-reported outcomes. In: Higgins JPT, Green S (Ed). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. Oxford: The Cochrane Collaboration; 2011. URL: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_17/17_patient_reported_outcomes.htm.
3. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010; 7(3): e1000251.
4. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 2013; 309(8): 814-822.
5. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10): e296.
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6(7): e1000097.
7. O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S (Ed). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. Oxford: The Cochrane Collaboration; 2011. URL: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_5/5_defining_the_review_question_and_developing_criteria_for.htm.
8. AHRQ. Chapter 1. Introduction to the Methods Guide for Medical Test Reviews. In: *Methods Guide for Medical Test Reviews*. AHRQ Publication No. 12-EC017. June 2012. Rockville: Agency for Healthcare Research and Quality; 2012. URL: http://effectivehealthcare.ahrq.gov/ehc/products/246/558/Methods-Guide-for-Medical-Test-Reviews_Full-Guide_20120530.pdf.
9. White CM, Ip S, McPheeters M, Carey TS, Chou R, Lohr KN et al. Using existing systematic reviews to replace de novo processes in conducting Comparative Effectiveness Reviews [posted September 2009]. In: *Methods Guide for Comparative Effectiveness Reviews*. Rockville: Agency for Healthcare Research and Quality; 2009. URL: <http://effectivehealthcare.ahrq.gov/repFiles/methodsguide/systematicreviewsreplacedenovofdf>.
10. Ebele JN, Sauter G, Epstein JI, Sesterhenn IA. *Pathology and genetics of tumours of the urinary system and male genital organs 2004*. Lyon: IARC Press; 2004. (World Health

1 *Subject: Reasons for excluding PRO studies*

2
3 Organization classification of tumours; Band 6). URL:

4 <http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/bb7-cover.pdf>.

5
6 11. Heidenreich A, Bolla M, Joniau S, Mason M, Matveev V, Mottet N et al. Guidelines on
7 prostate cancer [PDF on Internet] [online]. [Zugriff: 31 October 2012]. URL:

8 http://www.uroweb.org/gls/pdf/08_Prostate_Cancer.pdf.

9
10 12. AUA. Prostate cancer. Guideline for the management of clinically localized prostate
11 cancer: 2007 update [online]. 2007. URL: [http://www.auanet.org/content/guidelines-and-](http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf)
12 [quality-care/clinical-guidelines/main-reports/proscan07/content.pdf](http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf).

13
14 13. Nath R. Overview of brachytherapy physics. In: Thomadsen BR, Rivard MR, Butler W
15 (Ed). Brachytherapy physics. Madison: Medical Physics Publishing; 2005.

16
17 14. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review:
18 comparative effectiveness and harms of treatments for clinically localized prostate cancer.
19 Ann Intern Med 2008; 148(6): 435-448.

20
21 15. Koukourakis G, Kelekis N, Armonis V, Kouloulis V. Brachytherapy for prostate cancer:
22 a systematic review. Adv Urol 2009: 327945.

23
24 16. Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM et al.
25 American Society for Radiation Oncology (ASTRO) and American College of Radiology
26 (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
27 Int J Radiat Oncol Biol Phys 2011; 79(2): 335-341.

28
29 17. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Alibhai SM, Jewett MA et al.
30 Comparison of health-related quality of life 5 years after SPIRIT (Surgical Prostatectomy
31 [RP] versus Interstitial Radiation [BT] Intervention trial ACOSOG Z0070). Int J Radiat Oncol
32 Biol Phys 2010; 78(3 Suppl 1): S76.

33
34 18. Etter JF, Perneger TV. Analysis of non-response bias in a mailed health survey. J Clin
35 Epidemiol 1997; 50(10): 1123-1128.

36
37 19. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the
38 lost and wayward. Lancet 2002; 359(9308): 781-785.

39
40 20. Smeeth L, Fletcher AE. Improving the response rates to questionnaires. BMJ 2002;
41 324(7347): 1168-1169.

42
43 21. Brealey SD, Atwell C, Bryan S, Coulton S, Cox H, Cross B et al. Improving response
44 rates using a monetary incentive for patient completion of questionnaires: an observational
45 study. BMC Med Res Methodol 2007; 7: 12.

46
47 22. Edwards PJ, Roberts I, Clarke MJ, Diguiseppi C, Wentz R, Kwan I et al. Methods to
48 increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009;
49 (3): MR000008.

50
51 23. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al. Evaluating non-
52 randomised intervention studies. Health Technol Assess 2003; 7(27): iii-x, 1-173.

1 *Subject: Reasons for excluding PRO studies*

2
3 24. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG et al.
4 Comparison of evidence of treatment effects in randomized and nonrandomized studies.
5 JAMA 2001; 286(7): 821-830.
6

7 25. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized
8 studies [online]. (Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
9 [updated March 2011]). URL: [http://www.mrc-](http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_13/13_including_non_randomized_studies.htm)
10 [bsu.cam.ac.uk/cochrane/handbook/chapter_13/13_including_non_randomized_studies.htm](http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_13/13_including_non_randomized_studies.htm).
11

12 26. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included
13 studies. In: Higgins JPT, Green S (Ed). Cochrane Handbook for Systematic Reviews of
14 Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. (Band
15 25.05.2010). URL: [http://www.mrc-](http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm)
16 [bsu.cam.ac.uk/cochrane/handbook/chapter_8/8_assessing_risk_of_bias_in_included_studies.h](http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm)
17 [tm](http://www.mrc-bsu.cam.ac.uk/cochrane/handbook/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm).
18
19

20 27. Schmoor C, Gall C, Stampf S, Graf E. Correction of confounding bias in non-randomized
21 studies by appropriate weighting. Biometrical journal Biometrische Zeitschrift 2011; 53(2):
22 369-387.
23

24 28. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices
25 for comparative effectiveness research: approaches to mitigate bias and confounding in the
26 design of nonrandomized studies of treatment effects using secondary data sources: the
27 International Society for Pharmacoeconomics and Outcomes Research Good Research
28 Practices for Retrospective Database Analysis Task Force Report--Part II. Value in health :
29 the journal of the International Society for Pharmacoeconomics and Outcomes Research
30 2009; 12(8): 1053-1061.
31
32

33 29. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M et al. Health-related
34 quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy
35 for prostate cancer: a matched-pair comparison. Radiother Oncol 2009; 91(2): 225-231.
36

37 30. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on
38 quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166(5):
39 1804-1810.
40

41 31. Ball AJ, Gambill B, Fabrizio MD, Davis JW, Given RW, Lynch DF et al. Prospective
42 longitudinal comparative study of early health-related quality-of-life outcomes in patients
43 undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five
44 approaches from a single institution. J Endourol 2006; 20(10): 723-731.
45
46

47 32. Befort CA, Zelefsky MJ, Scardino PT, Borrayo E, Giesler RB, Kattan MW. A measure of
48 health-related quality of life among patients with localized prostate cancer: Results from
49 ongoing scale development. Clinical Prostate Cancer 2005; 4(2): 100-108.
50

51 33. Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for
52 localized prostate cancer. J Urol 2009; 182(2): 649-654.
53

54 34. Bergman J, Kwan L, Litwin MS. Improving decisions for men with prostate cancer:
55 translational outcomes research. J Urol 2010; 183(6): 2186-2192.
56
57
58
59
60

Subject: Reasons for excluding PRO studies

- 1
2
3 35. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after
4 brachytherapy for early stage prostate cancer. *J Urol* 2000; 163(3): 851-857.
5
6 36. Brown MW, Brooks JP, Albert PS, Poggi MM. An analysis of erectile function after
7 intensity modulated radiation therapy for localized prostate carcinoma. *Prostate Cancer*
8 *Prostatic Dis* 2007; 10(2): 189-193.
9
10 37. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR et
11 al. Erectile function outcome reporting after clinically localized prostate cancer treatment. *J*
12 *Urol* 2007; 178(2): 597-601.
13
14 38. Chaikin DC, Broderick GA, Malloy TR, Malkowicz SB, Whittington R, Wein AJ. Erectile
15 dysfunction following minimally invasive treatments for prostate cancer. *Urology* 1996;
16 48(1): 100-104.
17
18 39. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how
19 localized prostate cancer treatments affect patients with different levels of baseline urinary,
20 bowel, and sexual function. *J Clin Oncol* 2009; 27(24): 3916-3922.
21
22 40. Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C. Prospective survey of sexual
23 function among patients with clinically localized prostate cancer referred for definitive
24 radiotherapy and the impact of radiotherapy on sexual function. *Support Care Cancer* 2010;
25 18(6): 715-722.
26
27 41. Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA et al. Patients'
28 perceptions of quality of life after treatment for early prostate cancer. *J Clin Oncol* 2003;
29 21(20): 3777-3784.
30
31 42. Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS et al. Health related
32 quality of life patterns in patients treated with interstitial prostate brachytherapy for localized
33 prostate cancer--data from CaPSURE. *The Journal of urology* 2003; 170(5): 1822-1827.
34
35 43. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate
36 carcinoma: an examination of treatment-related, demographic, and psychosocial factors.
37 *Cancer* 2001; 92(6): 1451-1459.
38
39 44. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of
40 life following radical prostatectomy, high dose external beam radiation therapy and
41 brachytherapy iodine implantation as monotherapies for localized prostate cancer.[Erratum
42 appears in *J Urol*. 2007 Sep;178(3 Pt 1):1125]. *J Urol* 2007; 177(6): 2151-2156; discussion
43 2156.
44
45 45. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of
46 voiding and sexual function after treatment for localized prostate carcinoma: comparison of
47 radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy.
48 *Cancer* 2001; 91(11): 2046-2055.
49
50 46. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence:
51 48-month quality-of-life outcomes after treatment for localized prostate cancer. *J Natl Cancer*
52 *Inst* 2009; 101(12): 888-892.
53
54
55
56
57
58
59
60

Subject: Reasons for excluding PRO studies

- 1
2
3 47. Guedea F, Ferrer M, Pera J, Aguilo F, Boladeras A, Suarez JF et al. Quality of life two
4 years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for
5 clinically localised prostate cancer: the Catalan Institute of Oncology/Bellvitge Hospital
6 experience. *Clinical & Translational Oncology: Official Publication of the Federation of*
7 *Spanish Oncology Societies & of the National Cancer Institute of Mexico* 2009; 11(7): 470-
8 478.
9
10 48. Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M. A prospective
11 longitudinal study comparing a radical retropubic prostatectomy and permanent prostate
12 brachytherapy regarding the health-related quality of life for localized prostate cancer. *Jpn J*
13 *Clin Oncol* 2008; 38(7): 480-485.
14
15 49. Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M. Health-related
16 quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic
17 prostatectomy and permanent prostate brachytherapy. *Jpn J Clin Oncol* 2009; 39(8): 502-508.
18
19 50. Hervouet S, Savard J, Simard S, Ivers H, Laverdiere J, Vigneault E et al. Psychological
20 functioning associated with prostate cancer: cross-sectional comparison of patients treated
21 with radiotherapy, brachytherapy, or surgery. *J Pain Symptom Manage* 2005; 30(5): 474-484.
22
23 51. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG. Neoadjuvant
24 hormonal therapy and older age are associated with adverse sexual health-related quality-of-
25 life outcome after prostate brachytherapy. *Urology* 2002; 59(4): 480-484.
26
27 52. Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-
28 dose rate brachytherapy for prostate cancer: effects on health-related quality of life. *BJU Int*
29 2005; 96(1): 43-47.
30
31 53. Johnstone PA, Gray C, Powell CR. Quality of life in T1-3N0 prostate cancer patients
32 treated with radiation therapy with minimum 10-year follow-up. *Int J Radiat Oncol Biol Phys*
33 2000; 46(4): 833-838.
34
35 54. Joly F, Brune D, Couette JE, Lesaunier F, Heron JF, Peny J et al. Health-related quality of
36 life and sequelae in patients treated with brachytherapy and external beam irradiation for
37 localized prostate cancer. *Ann Oncol* 1998; 9(7): 751-757.
38
39 55. Kakehi Y, Takegami M, Suzukamo Y, Namiki S, Arai Y, Kamoto T et al. Health related
40 quality of life in Japanese men with localized prostate cancer treated with current multiple
41 modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer
42 Index Composite. *J Urol* 2007; 177(5): 1856-1861.
43
44 56. Lev EL, Eller LS, Gejerman G, Kolassa J, Colella J, Pezzino J et al. Quality of life of men
45 treated for localized prostate cancer: outcomes at 6 and 12 months. *Support Care Cancer*
46 2009; 17(5): 509-517.
47
48 57. Lilleby W, Fossa SD, Waehre HR, Olsen DR. Long-term morbidity and quality of life in
49 patients with localized prostate cancer undergoing definitive radiotherapy or radical
50 prostatectomy. *Int J Radiat Oncol Biol Phys* 1999; 43(4): 735-743.
51
52 58. Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment
53 for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. *The*
54 *Journal of urology* 2004; 172(2): 515-519.
55
56
57
58
59
60

Subject: Reasons for excluding PRO studies

59. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. *Cancer* 2007; 109(11): 2239-2247.

60. Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. *J Urol* 2003; 170(5): 1931-1933.

61. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23(12): 2772-2780.

62. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. *Urology* 2006; 68(1): 166-171.

63. Monahan PO, Champion V, Rawl S, Giesler RB, Given B, Given CW et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? *Qual Life Res* 2007; 16(3): 399-411.

64. Namiki S, Satoh T, Baba S, Ishiyama H, Hayakawa K, Saito S et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. *Urology* 2006; 68(6): 1230-1236.

65. Namiki S, Kwan L, Kagawa-Singer M, Terai A, Satoh T, Baba S et al. Distress and social dysfunction following prostate cancer treatment: a longitudinal cross-cultural comparison of Japanese and American men. *Prostate Cancer & Prostatic Diseases* 2009; 12(1): 67-71.

66. Ohashi T, Yorozu A, Toya K, Saito S, Momma T. Serial changes of international prostate symptom score following I-125 prostate brachytherapy. *Int J Clin Oncol* 2006; 11(4): 320-325.

67. Pinkawa M, Fishedick K, Gagel B, Piroth MD, Borchers H, Jakse G et al. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. *Urology* 2006; 68(1): 104-109.

68. Roach M, 3rd, Chinn DM, Holland J, Clarke M. A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 1996; 35(5): 869-874.

69. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. *N Engl J Med* 2008; 358(12): 1250-1261.

70. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C et al. Defining sexual outcomes after treatment for localized prostate carcinoma.[see comment]. *Cancer* 2002; 95(8): 1773-1785.

Subject: Reasons for excluding PRO studies

1
2
3 71. Soderdahl DW, Davis JW, Schellhammer PF, Given RW, Lynch DF, Shaves M et al.
4 Prospective longitudinal comparative study of health-related quality of life in patients
5 undergoing invasive treatments for localized prostate cancer. *Journal of endourology /*
6 *Endourological Society* 2005; 19(3): 318-326.
7

8 72. Speight JL, Elkin EP, Pasta DJ, Silva S, Lubeck DP, Carroll PR et al. Longitudinal
9 assessment of changes in sexual function and bother in patients treated with external beam
10 radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from
11 CaPSURE. *Int J Radiat Oncol Biol Phys* 2004; 60(4): 1066-1075.
12

13 73. Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG. Does neoadjuvant hormonal
14 therapy improve urinary function when given to men with large prostates undergoing prostate
15 brachytherapy? *J Urol* 2010; 183(2): 634-639.
16

17 74. Trojan L, Harrer K, Schafer J, Voss M, Welzel G, Bolenz C et al. [Complications and side
18 effects of low dose rate brachytherapy for the treatment of prostate cancer: data on a 13 year
19 follow-up study from Mannheim]. *Urologe A* 2007; 46(11): 1542-1547.
20

21 75. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men
22 with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no
23 definitive treatment: impact of age at diagnosis. *Cancer* 2006; 107(10): 2392-2400.
24

25 76. Valicenti RK, Bissondtte EA, Chen C, Theodorescu D. Longitudinal comparison of sexual
26 function after 3-dimensional conformal radiation therapy or prostate brachytherapy. *J Urol*
27 2002; 168(6): 2499-2504.
28

29 77. Van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS. Severity of cardiovascular
30 disease and health-related quality of life in men with prostate cancer: a longitudinal analysis
31 from CaPSURE. *Qual Life Res* 2008; 17(6): 845-855.
32

33 78. Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP. Health-related quality of life
34 after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer.
35 *Urol Int* 2009; 82(1): 17-23.
36

37 79. Zagar TM, Stock RG, Cesaretti JA, Stone NN. Assessment of postbrachytherapy sexual
38 function: a comparison of the IIEF-5 and the MSEFS. *Brachytherapy* 2007; 6(1): 26-33.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: Reasons for excluding PRO studies*

2
3 Figure legends

4
5 Figure 1. Study flow

6 Abbreviation. PICO: population, intervention, comparator, outcome; PRO: patient-reported
7 outcomes; RCT: randomised controlled trial
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Subject: Reasons for excluding PRO studies

Figure 1. Study flow

1 *Subject: Reasons for excluding PRO studies*

2
3 Table 1. Search strategy.

4 Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid
5 MEDLINE(R) Daily and Ovid MEDLINE(R) <1950 to Present>

No	Search term
1	PROSTATIC NEOPLASMS/
2	(prostat* adj6 (cancer* or carcinom* or tumor* or tumour* or neoplasm* or adenocar- cinom*)).ab,ti.
3	or/1-2
4	BRACHYTHERAPY/
5	brachytherap*.ab,ti.
6	((interstit* or implant*) adj6 (radiation* or radiotherapy*)).ab,ti.
7	((seed* or permanent*) adj6 implant*).ab,ti.
8	or/4-7
9	3 and 8
10	RANDOMIZED CONTROLLED TRIAL.pt.
11	CONTROLLED CLINICAL TRIAL.pt.
12	RANDOMIZED CONTROLLED TRIALS AS TOPIC/
13	RANDOM ALLOCATION/
14	DOUBLE BLIND METHOD/
15	SINGLE BLIND METHOD/
16	or/10-15
17	ANIMAL/ not HUMAN/
18	16 not 17
19	CLINICAL TRIAL.pt.
20	exp CLINICAL TRIALS AS TOPIC/
21	(clinic* adj25 trial*).tw.
22	((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw.
23	PLACEBOS/
24	placebo*.tw.
25	random*.tw.
26	RESEARCH DESIGN/
27	(latin adj square).tw.
28	or/19-27
29	28 not 17
30	29 not 18
31	COMPARATIVE STUDY.pt.
32	exp EVALUATION STUDIES/
33	FOLLOW UP STUDIES/
34	PROSPECTIVE STUDIES/
35	(control* or prospectiv* or volunteer*).tw.
36	CROSS-OVER STUDIES/
37	or/31-36
38	37 not 17
39	38 not (18 or 30)

Subject: Reasons for excluding PRO studies

- 1
2
3 40 18 or 30 or 39
4 41 exp CASE-CONTROL STUDIES/
5 42 exp COHORT STUDIES/
6
7 43 ((compare* or comparison* or versus or evaluation or follow up or case-control*) adj8
8 (stud* or trial* or analy*).ab,ti.
9 44 ((cohort* or observation* or intervention*) adj3 (stud* or trial* or analy*).ab,ti.
10 45 exp CONTROL GROUPS/
11 46 exp MULTICENTER STUDIES/
12 47 (multi center adj3 stud*).ab,ti.
13 48 or/41-47
14 49 40 or 48
15 50 search*.tw. or META ANALYSIS.mp.pt. or REVIEW.pt.
16 51 9 and (49 or 50)
-

Subject: Reasons for excluding PRO studies

Table 1. Reasons for excluding PRO articles

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Bacon 2001 [30]	yes	yes	NO	-	-	-	-	-	No concurrent group
Ball 2006 [31]	yes	yes	NO	-	-	-	-	-	Cryotherapy
Befort 2005 [32]	yes	yes	yes	yes	NO	-	-	-	Low response
Bergman 2009 [33]	yes	yes	yes	yes	yes	yes	yes	NO	No appropriate test
Bergman 2010 [34]	yes	yes	yes	yes	NO	-	-	-	Low response
Brandeis 2000 [35]	yes	NO	-	-	-	-	-	-	29% LDR-BT + EBRT
Brown 2007 [36]	yes	NO	-	-	-	-	-	-	EBRT
Burnett 2007 [37]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Chaikin 1996 [38]	NO	-	-	-	-	-	-	-	Staging not reported
Chen 2009 [39]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Choo 2010 [40]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Clark 2003 [41]	yes	yes	yes	yes	NO	-	-	-	Low response
Downs 2003 [42]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Eton 2001 [43]	yes	yes	yes	yes	NO	-	-	-	Low response
Frank 2007 [44]	yes	yes	yes	yes	NO	-	-	-	Low response
Fulmer 2001 [45]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Gore 2009 [46]	yes	yes	yes	yes	NO	-	-	-	Low response
Guedea 2009 [47]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2008 [48]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2009 [49]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hervouet 2005 [50]	NO	-	-	-	-	-	-	-	≥20% T3-T4 in control groups
Hollenbeck 2002 [51]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Jo 2005 [52]	yes	NO	-	-	-	-	-	-	High-dose rate brachytherapy
Johnstone 2000 [53]	yes	NO	-	-	-	-	-	-	EBRT
Joly 1998 [54]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Kakehi 2007 [55]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Lev 2009 [56]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Lilleby 1999 [57]	yes	NO	-	-	-	-	-	-	EBRT
Litwin 2004 [58]	yes	yes	yes	yes	NO	-	-	-	Low response
Litwin 2007 [59]	yes	NO	-	-	-	-	-	-	25% LDR-BT + EBRT
Mehta 2003 [60]	yes	yes	yes	NO	-	-	-	-	"Fear of cancer"

Subject: Reasons for excluding PRO studies

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Miller 2005 [61]	yes	NO	-	-	-	-	-	-	44% LDR-BT + EBRT
Miller 2006 [62]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Monahan 2007 [63]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2006 [64]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2009 [65]	yes	yes	yes	yes	NO	-	-	-	Low response
Ohashi 2006 [66]	yes	yes	yes	yes	NO	-	-	-	Low response
Pinkawa 2006 [67]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Roach 1996 [68]	yes	NO	-	-	-	-	-	-	EBRT, single-arm trial
Sanda 2008 [69]	yes	yes	yes	yes	NO	-	-	-	Low response
Schover 2002 [70]	yes	yes	yes	yes	NO	-	-	-	Low response
Soderdahl 2005 [71]	yes	yes	yes	yes	NO	-	-	-	Low response
Speight 2004 [72]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Stone 2010 [73]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Trojan 2007 [74]	yes	yes	yes	yes	NO	-	-	-	Low response
Tward 2006 [75]	yes	yes	yes	NO	-	-	-	-	Mortality differs [§]
Valicenti 2002 [76]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Van de Poll-F 2008 [77]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Wyler 2009 [78]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Zagar 2007 [79]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
"NO" counts	2	13	4	2	19	3	6	1	Total: 50 studies
	PICO not met: 21				High risk of bias: 29				


-: not appropriate

*Mehta 2003: no appropriate endpoint

[†]Pinkawa 2006; Stone 2010: neoadjuvant hormonal therapy

[§]Tward 2006: non-disease-related mortality differs greatly

Abbreviations: C: comparison of interest is radical prostatectomy, external beam radiotherapy, or no primary therapy; EBRT: external beam radiotherapy; I: intervention of interest is low-dose rate brachytherapy as monotherapy; LDR-BT: low-dose rate brachytherapy; O: outcome of interest is function, bother, or generic health-related quality of life; P: patients with localized prostate cancer; PRO: patient-reported outcomes



Study flow
170x235mm (96 x 96 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	none
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8-9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	none
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	none
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	none
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	none
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	none
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	none
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11-14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Failure to address potential bias in nonrandomized controlled clinical trials may cause lack of evidence on patient-reported outcomes - a method study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004720.R1
Article Type:	Research
Date Submitted by the Author:	28-Apr-2014
Complete List of Authors:	Peinemann, Frank; Children's Hospital, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany, Labeit, Alexander; University of Illinois, Outcomes Research Center Thielscher, Christian; FOM University of Applied Science for Economics & Management, Pinkawa, Michael; University Hospital, Department of Radiotherapy
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Urology, Patient-centred medicine, Evidence based practice
Keywords:	Adult surgery < SURGERY, Radiation oncology < RADIOTHERAPY, Urological tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3
4 Failure to address potential bias in nonrandomized controlled clinical trials may cause lack of
5
6 evidence on patient-reported outcomes – a method study
7

8
9 Frank Peinemann,^{1,*} Alexander Michael Labeit,² Christian Thielscher,³ Michael Pinkawa,⁴

10
11 ¹Children's Hospital, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

12 ²Outcomes Research Center, University of Illinois, One Illini Drive, Peoria, IL 61656, USA

13 ³FOM University of Applied Science for Economics & Management, Leimkugelstr. 6, 45141
14
15 Essen, Germany

16
17 ⁴Department of Radiotherapy, University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany

18
19
20
21 FP: pubmedprjournal@gmail.com

22
23 AML: alabeit.publications@gmail.com

24
25 CT: christian.thielscher@fom.de

26
27 MP: mpinkawa@ukaachen.de

28
29
30
31
32
33 *Corresponding author: Frank Peinemann, M.D., M.Sc., Children's Hospital, University of
34 Cologne, Kerpener Str. 62, 50937 Cologne, Germany; e-mail: pubmedprjournal@gmail.com.
35
36 Phone: +49-176-31130745.
37

38
39
40 Word count, excluding title page, abstract, references, figures and tables: 6102
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Abstract

Objectives: We conducted a workup of a previously published systematic review and aimed to analyse why most of the identified nonrandomized controlled clinical trials with patient-reported outcomes did not match a set of basic quality criteria.

Setting: There were no limits on the level of care and the geographical location.

Participants: The review evaluated permanent interstitial low-dose rate brachytherapy in patients with localized prostate cancer and compared that intervention to alternative procedures such as external beam radiotherapy, radical prostatectomy, and no primary therapy.

Primary outcome measure: Fulfilment of basic inclusion criteria according to a PICO framework and accomplishment of requirements to contain superimposed risk of bias.

Results: We found that 21 of 50 excluded nonrandomized controlled trials did not meet PICO inclusion criteria. The rest of 29 of 50 studies lacked quality of reporting. The resulting flaws included attrition bias due to loss of follow-up, lack of reporting baseline data, potential confounding due to unadjusted data and lack of statistical comparison between groups.

Conclusions: With respect to the reporting of patient-reported outcomes, active efforts are required to improve the quality of reporting in nonrandomized controlled trials concerning permanent interstitial low-dose rate brachytherapy in patients with localized prostate cancer.

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Key words: systematic review, patient-reported outcome, risk of bias

Strengths and limitations of this study

- We conducted a comprehensive literature search and strictly adhered to the projected methodology.
- We identified a lack of quality in nonrandomized controlled clinical trials reporting patient-reported outcomes, analysed the cause, and suggested possible improvements in designing studies in the future.
- The analysis is confined to a single disease and a specific treatment and conclusions drawn from its results may not be generalizable to other diseases and treatments.
- The limits for the inclusion of studies are arbitrarily set.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Abbreviation	Term
CCT	Nonrandomized controlled clinical trial
CONSORT	Consolidated standards of reporting trials
EBRT	External beam radiotherapy
EMBASE	Excerpta medica database
LDR-BT	Permanent interstitial low-dose rate brachytherapy
MEDLINE	Medical literature analysis and retrieval system online
PICO (TS-SD)	Participants, intervention, comparator, outcome (timing, setting, study design)
PRO	Patient-reported outcome
RCT	Randomized controlled trial
STROBE	Strengthening the reporting of observational studies in epidemiology
TNM	Tumor-Node-Metastasis

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Introduction

The present paper reports a workup of a previously published systematic review [1]. It may be regarded as a methodological supplement adding information on a subset of excluded studies. We have compared permanent interstitial low-dose rate brachytherapy, with radical prostatectomy, external beam radiotherapy, and 'no primary therapy' in patients with localized prostate cancer categorized T1 to T2. We used the term 'no primary therapy' to accommodate different types of observation including active surveillance, watchful waiting, and observing without a distinctive management. As a result, we included one randomized controlled trial (RCT) and 30 nonrandomized controlled clinical trials (CCT). The primary outcome was overall survival. The secondary outcomes were clinically defined disease-free survival, biochemical recurrence-free survival, physician-reported severe adverse events, and patient-reported outcomes such as function and bother scores as well as generic and disease-related health-related quality of life. We concluded that the current evidence is insufficient to allow a definitive conclusion about overall survival. Radical prostatectomy and external beam radiotherapy can severely affect the structural integrity of neighboring organs and their functions and can cause considerable long-term impairment of health-related quality of life. In a view of expecting similar survival but a tremendous difference of adverse events between treatment alternatives, valid data on health-related quality of life could tip the balance. At least, we assume that shared-decision making and consideration of patients' preferences in searching for the best individual treatment would rely on information on health-related quality of life data. Of the 30 included nonrandomized studies, 13 studies reported patient-reported outcomes (PROs), that is, only the patients provided the information [2]. During the study selection process, we experienced that we excluded another 50 nonrandomized PRO studies. We found it a pity that we could not use the many data. We had the impression that a considerable number of studies were excluded because of lack in reporting quality. Therefore,

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 we wanted to summarize the reasons for excluding those PRO studies and make aware that
4
5 authors of PRO studies should meet some basic requirements for reporting of comparative
6
7 PRO data to achieve higher acceptance in the scientific community. The importance of
8
9 reporting PRO has been addressed by the Consolidated Standards of Reporting Trials
10
11 (CONSORT) group [3] that recently has published a PRO extension to their acclaimed
12
13 previous statement [4]. It may be wise to build a PRO extension to the STrengthening the
14
15 Reporting of OBServational studies in Epidemiology (STROBE) statement [5] that addresses
16
17 specific issues of observational studies.
18
19

20
21 The first aim of this study was to assess whether the excluded studies met the basic inclusion
22
23 criteria using the PICO framework. The second aim of this study was whether the excluded
24
25 studies met requirements to contain high risk of bias.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 3 **Materials and Methods**

4 5 6 **Study inclusion criteria**

7
8
9
10 We defined the inclusion criteria according to the PICO framework that should include four
11 essential constituents, that is, the type of participants (P), intervention (I), comparator (C), and
12 outcome (O) [6]. The four PICO items can be supplemented by timing (T) and setting (S), two
13 other important features of a systematic review, to create the so-called PICOTS typology [7].
14
15 A further extension embraces the study design (SD) to complete all major items of a search
16 strategy (PICOTS-SD) [8].
17
18
19
20
21
22

23 24 *Population*

25
26
27 Initial and present publication: Localized prostate cancer is defined by the categories T1 to T2
28 of the Tumor-Node-Metastasis (TNM) staging system [9] if combined with an absence of
29 both regional lymph node metastasis and distant metastasis.
30
31
32
33

34 35 *Intervention*

36
37
38 Initial and present publication: Brachytherapy [10] is short-distance radiotherapy placing
39 radiation sources with different duration and rates of dose delivery in or near tumors [11].
40
41 Permanent interstitial low-dose rate brachytherapy means implanting of low-energy
42 radioactive sources emitting radiation, which are contained in titanium pellets of the size of
43 rice grains called seeds [12].
44
45
46
47
48
49

50 51 *Comparator*

52
53
54 Initial and present publication: The European Association of Urology suggested 3 different
55 treatment concepts for localized prostate cancer in addition to permanent interstitial low-dose
56 rate brachytherapy [10]: Radical prostatectomy, external beam radiotherapy, and different
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 types of observation including active surveillance, watchful waiting, and observing without a
3
4 distinctive management.
5
6

7
8 *Outcome*
9

10
11 Initial publication: Overall survival, cancer-specific survival, disease-free survival,
12 biochemical recurrence-free survival, severe adverse events, and patient-reported outcomes.
13 Patient-reported outcomes comprised function and bother scores as well as generic and
14 disease-related health-related quality of life.
15
16
17
18
19

20
21 Present publication: Fulfilment of basic inclusion criteria according to a PICO framework by
22 the excluded CCT. Accomplishment of requirements to contain superimposed risk of bias in
23 addition to the high risk of bias caused by the lack of randomization framework by the
24 excluded CCT.
25
26
27
28
29

30
31 *Timing*
32

33
34 Initial and present publication: We did not set limits on the length of the observation period.
35
36

37
38 *Setting*
39

40
41 Initial and present publication: We did not set limits on the setting such as type of country,
42 year of recruitment, or level of health care.
43
44

45
46 *Study design*
47

48
49 Initial publication: We included RCT and CCT evaluating permanent interstitial low-dose rate
50 brachytherapy as monotherapy in patients with localized prostate cancer. The proportion of
51 relevant patients was required to be at least 80% of the study population and the response rate
52 of questionnaires was expected to be at least 70%. For CCT to be included, comparable base-
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 line characteristics between treatment groups or adjustment for imbalances of these data were
4
5 required. Limits on year of publication or language were not applied.
6
7

8 Present publication: We included specifically the CCT that were excluded in the initial
9
10 publication.
11

12 13 **Search strategy**

14
15
16
17 The search strategy was reported previously [1].
18
19

20 **Study selection**

21
22
23 In the present study, we selected only those 50 nonrandomized studies on PRO that were ex-
24
25 cluded from the evaluation in the initial publication. In the study selection process, two re-
26
27 viewers independently judged whether a study was included or excluded. Differences were
28
29 resolved by discussion without the need for a third opinion.
30
31

32 **Data collection and analysis**

33
34
35
36 The reasons for exclusion were extracted independently by two reviewers. We sought for the
37
38 following data: the inclusion criteria using the PICO framework, the proportion of response of
39
40 participants to questionnaires, which was required to be at least 70%, the reporting of separate
41
42 baseline characteristics for each treatment group, the reporting of comparable baseline charac-
43
44 teristics or adjustment for imbalances of these data such as the use of a Cox proportional haz-
45
46 ard model, and the reporting of statistics comparing treatment groups. Sufficient comparabil-
47
48 ity was defined as a difference between baseline values that were not statistically significant.
49
50 If a statistical test was not reported, we assumed two comparable values if the greater of the
51
52 two values was less than 10% above the smaller one. We also required that authors reported
53
54 effect measures and statistics testing the difference between treatment groups, for example, p-
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 values or effect measures including 95% confidence intervals. Reporting of within group
3 comparisons or before-and-after analyses was not deemed sufficient for inclusion. We did not
4 apply a principal summary measure as we aimed at synthesize the information in a qualitative
5 way.
6
7
8
9
10

11 **Assessment of risk of bias and quality of reporting**

12
13 Two reviewers independently assessed the quality of reporting of CCT according to the crite-
14 ria specified in the previous paragraph. We did not specifically assess the risk of bias because
15 we decided to exclude all papers with regard to a lack of reporting essential data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 3 **Results**

4
5
6
7 Of a total of 462 full-text articles assessed for eligibility in the previously published systemat-
8
9 ic review, 31 studies were included and 431 studies were excluded. Among the 431 excluded
10
11 articles, we identified 50 nonrandomised studies that were reporting on PRO (Figure 1). We
12
13 evaluated the reasons for exclusion of those 50 studies and documented the results in Table 1.
14
15 In 42% (21 of 50) studies, simply the essential PICO framework was not met. In the majority
16
17 of 58% (29 of 50) studies, the predefined requirement to apply measures to contain high risk
18
19 of bias was not met. Of these 29 studies, 19 studies reported a proportion of patients respond-
20
21 ing to questionnaires of less than 70% or did not address this item. Baseline characteristics
22
23 were not presented for treatment groups in 3 studies. In another 6 studies, baseline character-
24
25 istics were not comparable between treatment groups or there was no confounder control in
26
27 the analysis adjusting for important different factors such as mean age. The statistical compar-
28
29 ison between treatment groups was deemed not appropriate in 1 study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Discussion

Main results

In summary, we found that roughly 4 of 10 excluded PRO studies did not meet the essential inclusion criteria using the PICO framework. This result is consistent with the problem of information retrieval aiming at a high recall and ending up with a low precision. The papers were obviously not relevant to the research question and we did not further examine the reporting quality. We also found that roughly 6 of 10 excluded PRO studies met the PICO framework but did not provide predefined requirements to care sufficiently enough for a low response of patients to questionnaires, for reporting baseline characteristics between treatment groups, for adjusting differences in those baseline characteristics between treatment groups, and to use appropriate statistics to compare the outcome between treatment groups.

Quality of reporting of patient-reported outcomes

We identified a lack of quality of reporting in many excluded CCT and we want to stress the importance of considering a series of requirements while conducting a study on PRO. Other authors have reported recently that, concerning disease-specific mortality or disease-free survival, available studies did not show significant differences between treatment groups. [13 14]. In view of unknown or small differences in survival measures, the results of patient-reported outcomes studies could have a noticeable impact on medical decision making [15 16]. None of the 50 excluded studies reported a non-responder analysis, though it is known that non-responders may have different attitudes than responders. Etter 1997 concluded that low response rates may be associated with overestimating an effect and that the strength and direction of a non-response bias may depend on the mechanism of non-response [17]. Therefore, results may be confounded if the proportion of included data not available for analysis

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 such as data from non-responders or due to loss to follow-up is considerable. We believe that
3 a value of 30% or more can be denoted as considerable. Lowering this threshold, for example
4 a value of 30% or more can be denoted as considerable. Lowering this threshold, for example
5 to 20%, would have resulted in less included studies. However, others suggested that 20% or
6 more loss would be sufficient for a high risk of bias threatening the validity of results [18].
7 Concerning questionnaires, we recommend taking measures that are known to improve re-
8 sponse rates [19 20]. Edwards 2009 conducted a systematic review to identify effective strat-
9 egies to increase the response to postal and electronic questionnaires [21]. The authors found
10 several strategies to increase the response, for example, pre-notification, follow-up contact,
11 shorter questionnaires, mentioning an obligation to respond, university sponsorship, non-
12 monetary incentives, a statement that others had responded, an offer of survey results, giving
13 a deadline. We did not use a strict algorithm to differentiate between comparable and not
14 comparable baseline values between treatment groups. A statistically significant difference
15 was judged as not comparable. Not significant differences were also regarded as not compa-
16 rable if the difference was at least 10% of the lower of two values. Using this approach we
17 tried to reduce subjective decisions. We are not aware of published strict algorithms in this
18 matter.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **High risk of bias inherent in nonrandomized controlled trials**

39 In the view of including only 1 RCT, the initial publication was based almost exclusively on
40 CCT. However, the lack of randomization poses a very large challenge on the authors that are
41 advised to deal with essential problems such as selection bias and confounding. Otherwise,
42 the findings may not be valid and of limited usefulness and the many efforts may be in vain.
43 We want to stress that the nonrandomized design is associated with a high risk of bias because
44 known and unknown characteristics may be distributed unequally between groups [22].
45 Certain study characteristics such as prospective design, concurrent control group, adjustment
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 of results with respect to different baseline values, and confounder control can limit additional
4
5 bias. For example, Ioannidis 2001 [23] reported that discrepancies between RCT and CCT
6
7 were less common when only CCT with a prospective design were considered. The Cochrane
8
9 Collaboration offers a guide for inclusion of nonrandomized studies [24] and it has developed
10
11 a tool for assessing the risk of bias in both RCT and CCT [25]. Guidelines for reporting ob-
12
13 servational studies have been published to improve their quality [5]. Cox regression analysis,
14
15 propensity-score-based analysis, and instrumental variable analysis are methods that have
16
17 been used for correction of confounding bias in non-randomized studies [26]. Different values
18
19 of various outcome measures between groups may be simply caused by different baseline data
20
21 in lieu of absent significant treatment effects. We accepted any type of method adjusting or
22
23 stratifying for one or more known differences in baseline characteristics. Nevertheless, it
24
25 should be kept in mind that methods of adjustment do not guarantee removal of bias and that
26
27 residual confounding may remain high [22]. Concerning the non-randomized design, we
28
29 strongly recommend the use of methods for adjusting the results for confounders to aim for a
30
31 less biased estimation of the treatment effect [27] and the adoption of guidelines for the re-
32
33 porting of observational studies [5].
34
35
36
37
38

39 **Strengths and limitations**

40
41
42 The strengths of the present study are a comprehensive literature search, strict adherence to
43
44 the projected methodology, the identification of lack of quality in PRO studies and addressing
45
46 the specific problems of PRO studies. We should consider some limitations: The study is con-
47
48 fined to a single disease and conclusions drawn from its results may not be generalizable to
49
50 other diseases. The arbitrary limits set for inclusion of studies are responsible for the extent of
51
52 excluded studies. These limits may be questioned by other investigators. During re-evaluation
53
54 of study quality, we found that one study fulfilled all criteria, although, this study was exclud-
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 ed in previous reports [28]. The minimum follow-up of 70% for inclusion was set arbitrarily
3 and others might find this threshold too low. We did not endorse the recently published re-
4 porting of PRO in randomized trials, an extension of the CONSORT statement [4]. All in-
5 cluded studies in the present review are nonrandomized. We think that the lack of randomiza-
6 tion is the prevailing issue. We did not endorse the CONSORT PRO extension for another
7 reason. The included studies were published many years before this extension was published.
8 There might be a need to develop an extension of the STROBE statement [5] aiming to im-
9 prove the reporting of PRO in nonrandomized studies. This extension could emphasize the
10 specific challenges of reporting PRO with respect to lack of randomization.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Conclusions

We found that a considerable number of non-randomized controlled reporting patient-reported outcomes were excluded from a systematic review because of a lack of predefined reporting requirements. The assumed overall risk of bias was regarded too high to consider the data of these studies for inclusion in the systematic review. With respect to the reporting of patient-reported outcomes, active efforts are required to improve the quality of reporting in nonrandomized controlled trials and to increase the number of randomized controlled trials.

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 **Acknowledgements:** Parts of the study have been presented at 19th Cochrane Colloquium 19
4
5 to 22 October 2011 in Madrid, Spain.
6
7

8 **Funding:** This research received no specific grant from any funding agency in the public,
9
10 commercial or not-for-profit sectors. The University of Cologne provided full-texts. The fun-
11
12 ders had no role in study design, data collection and analysis, decision to publish, or prepara-
13
14 tion of the manuscript.
15
16

17
18 **Author contribution:** Conceived and designed the experiments: FP. Performed the experi-
19
20 ments: FP. Analysed the data: FP, MP. Wrote the manuscript: FP, AML, CT, MP.
21
22

23 **Competing interests:** None
24
25

26 **Data Sharing Statement:** No additional data are available
27
28

29
30 **Reporting guidelines:** PRISMA checklist is attached
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

References

1. Peinemann F, Grouven U, Bartel C, et al. Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer – a systematic review of randomized and non-randomized controlled clinical trials. *Eur Urol* 2011;**60**(5):881-93
2. Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient-reported outcomes. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane Collaboration, 2011.
3. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010;**7**(3):e1000251
4. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 2013;**309**(8):814-22
5. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007;**4**(10):e296
6. O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane Collaboration, 2011.
7. *Methods Guide for Medical Test Reviews*. AHRQ Publication No. 12-EC017. Rockville: Agency for Healthcare Research and Quality, 2012.
8. White CM, Ip S, McPheeters M, et al. Using existing systematic reviews to replace de novo processes in conducting Comparative Effectiveness Reviews. *Methods Guide for Comparative Effectiveness Reviews*. Rockville: Agency for Healthcare Research and Quality, 2009.
9. Ebele JN, Sauter G, Epstein JI, et al. *Pathology and genetics of tumours of the urinary system and male genital organs*. Lyon: IARC Press, 2004.
10. Heidenreich A, Bolla M, Joniau S, et al. *Guidelines on prostate cancer*. Arnhem: European Association of Urology, 2011.
11. *Prostate cancer. Guideline for the management of clinically localized prostate cancer: 2007 update*. Linthicum: American Urological Association, 2007.
12. Nath R. Overview of brachytherapy physics. In: Thomadsen BR, Rivard MR, Butler W, eds. *Brachytherapy physics*. Second ed. Madison: Medical Physics Publishing, 2005.
13. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. *Ann Intern Med* 2008;**148**(6):435-48

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
- 3 14. Koukourakis G, Kelekis N, Armonis V, et al. Brachytherapy for prostate cancer: a
4 systematic review. *Adv Urol* 2009;327945
- 5
- 6 15. Rosenthal SA, Bittner NH, Beyer DC, et al. American Society for Radiation Oncology
7 (ASTRO) and American College of Radiology (ACR) practice guideline for the
8 transperineal permanent brachytherapy of prostate cancer. *Int J Radiat Oncol Biol Phys*
9 2011;**79**(2):335-41
- 10
- 11 16. Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of health-related quality of
12 life 5 years after SPIRIT (Surgical Prostatectomy [RP] versus Interstitial Radiation [BT]
13 Intervention trial ACOSOG Z0070). *Int J Radiat Oncol Biol Phys* 2010;**78**(3 Suppl
14 1):S76
- 15
- 16
- 17 17. Etter JF, Perneger TV. Analysis of non-response bias in a mailed health survey. *J Clin*
18 *Epidemiol* 1997;**50**(10):1123-8
- 19
- 20 18. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the
21 lost and wayward. *Lancet* 2002;**359**(9308):781-5
- 22
- 23 19. Smeeth L, Fletcher AE. Improving the response rates to questionnaires. *BMJ*
24 2002;**324**(7347):1168-9
- 25
- 26 20. Brealey SD, Atwell C, Bryan S, et al. Improving response rates using a monetary
27 incentive for patient completion of questionnaires: an observational study. *BMC Med*
28 *Res Methodol* 2007;**7**:12
- 29
- 30 21. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and
31 electronic questionnaires. *Cochrane Database Syst Rev* 2009(3):MR000008
- 32
- 33 22. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies.
34 *Health Technol Assess* 2003;**7**(27):iii-x, 1-173
- 35
- 36 23. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in
37 randomized and nonrandomized studies. *JAMA : the journal of the American Medical*
38 *Association* 2001;**286**(7):821-30
- 39
- 40 24. Reeves BC, Deeks JJ, Higgins JPT, et al. Chapter 13: Including non-randomized studies.
41 In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of*
42 *Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane
43 *Collaboration*, 2011.
- 44
- 45 25. Higgins JPT, Altman DG, Sterne JAC. Chapter 8 Assessing risk of bias in included
46 studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of*
47 *Interventions* Version 510 [updated March 2011]. Oxford: The Cochrane Collaboration,
48 2011.
- 49
- 50 26. Schmoor C, Gall C, Stampf S, et al. Correction of confounding bias in non-randomized
51 studies by appropriate weighting. *Biom J* 2011;**53**(2):369-87
- 52
- 53 27. Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative
54 effectiveness research: approaches to mitigate bias and confounding in the design of
55 nonrandomized studies of treatment effects using secondary data sources: the
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. *Value Health* 2009;**12**(8):1053-61

28. Pinkawa M, Asadpour B, Piroth MD, et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer: a matched-pair comparison. *Radiother Oncol* 2009;**91**(2):225-31
29. Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. *J Urol* 2001;**166**(5):1804-10
30. Ball AJ, Gambill B, Fabrizio MD, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. *J Endourol* 2006;**20**(10):723-31
31. Befort CA, Zelefsky MJ, Scardino PT, et al. A measure of health-related quality of life among patients with localized prostate cancer: Results from ongoing scale development. *Clinical Prostate Cancer* 2005;**4**(2):100-08
32. Bergman J, Gore JL, Penson DF, et al. Erectile aid use by men treated for localized prostate cancer. *J Urol* 2009;**182**(2):649-54
33. Bergman J, Kwan L, Litwin MS. Improving decisions for men with prostate cancer: translational outcomes research. *J Urol* 2010;**183**(6):2186-92
34. Brandeis JM, Litwin MS, Burnison CM, et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. *J Urol* 2000;**163**(3):851-57
35. Brown MW, Brooks JP, Albert PS, et al. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. *Prostate Cancer Prostatic Dis* 2007;**10**(2):189-93
36. Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. *J Urol* 2007;**178**(2):597-601
37. Chaikin DC, Broderick GA, Malloy TR, et al. Erectile dysfunction following minimally invasive treatments for prostate cancer. *Urology* 1996;**48**(1):100-04
38. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. *J Clin Oncol* 2009;**27**(24):3916-22
39. Choo R, Long J, Gray R, et al. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. *Support Care Cancer* 2010;**18**(6):715-22
40. Clark JA, Inui TS, Silliman RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. *J Clin Oncol* 2003;**21**(20):3777-84

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
- 3 41. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients
4 treated with interstitial prostate brachytherapy for localized prostate cancer--data from
5 CaPSURE. *J Urol* 2003;**170**(5):1822-7
- 6
- 7 42. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate
8 carcinoma: an examination of treatment-related, demographic, and psychosocial factors.
9 *Cancer* 2001;**92**(6):1451-9
- 10
- 11 43. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical
12 prostatectomy, high dose external beam radiation therapy and brachytherapy iodine
13 implantation as monotherapies for localized prostate cancer. *J Urol* 2007;**177**(6):2151-56
- 14
- 15 44. Fulmer BR, Bissonette EA, Petroni GR, et al. Prospective assessment of voiding and
16 sexual function after treatment for localized prostate carcinoma: comparison of radical
17 prostatectomy to hormonobrachytherapy with and without external beam radiotherapy.
18 *Cancer* 2001;**91**(11):2046-55
- 19
- 20 45. Gore JL, Kwan L, Lee SP, et al. Survivorship beyond convalescence: 48-month quality-
21 of-life outcomes after treatment for localized prostate cancer. *J Natl Cancer Inst*
22 2009;**101**(12):888-92
- 23
- 24 46. Guedea F, Ferrer M, Pera J, et al. Quality of life two years after radical prostatectomy,
25 prostate brachytherapy or external beam radiotherapy for clinically localised prostate
26 cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. *Clin Transl*
27 *Oncol* 2009;**11**(7):470-78
- 28
- 29 47. Hashine K, Kusuhara Y, Miura N, et al. A prospective longitudinal study comparing a
30 radical retropubic prostatectomy and permanent prostate brachytherapy regarding the
31 health-related quality of life for localized prostate cancer. *Jpn J Clin Oncol*
32 2008;**38**(7):480-85
- 33
- 34 48. Hashine K, Kusuhara Y, Miura N, et al. Health-related quality of life using SF-8 and
35 EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent
36 prostate brachytherapy. *Jpn J Clin Oncol* 2009;**39**(8):502-08
- 37
- 38 49. Hervouet S, Savard J, Simard S, et al. Psychological functioning associated with prostate
39 cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy,
40 or surgery. *J Pain Symptom Manage* 2005;**30**(5):474-84
- 41
- 42 50. Hollenbeck BK, Dunn RL, Wei JT, et al. Neoadjuvant hormonal therapy and older age are
43 associated with adverse sexual health-related quality-of-life outcome after prostate
44 brachytherapy. *Urology* 2002;**59**(4):480-4
- 45
- 46 51. Jo Y, Junichi H, Tomohiro F, et al. Radical prostatectomy versus high-dose rate
47 brachytherapy for prostate cancer: effects on health-related quality of life. *BJU Int*
48 2005;**96**(1):43-47
- 49
- 50 52. Johnstone PA, Gray C, Powell CR. Quality of life in T1-3N0 prostate cancer patients
51 treated with radiation therapy with minimum 10-year follow-up. *Int J Radiat Oncol Biol*
52 *Phys* 2000;**46**(4):833-8
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

53. Joly F, Brune D, Couette JE, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. *Ann Oncol* 1998;**9**:(7):751-57
54. Kakehi Y, Takegami M, Suzukamo Y, et al. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. *J Urol* 2007;**177**(5):1856-61
55. Lev EL, Eller LS, Gejerman G, et al. Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months. *Support Care Cancer* 2009;**17**(5):509-17
56. Lilleby W, Fossa SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. *Int J Radiat Oncol Biol Phys* 1999;**43**(4):735-43
57. Litwin MS, Sadetsky N, Pasta DJ, et al. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. *J Urol* 2004;**172**(2):515-9
58. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. *Cancer* 2007;**109**(11):2239-47
59. Mehta SS, Lubeck DP, Pasta DJ, et al. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. *J Urol* 2003;**170**:(5):1931-33
60. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *J Clin Oncol* 2005;**23**(12):2772-80
61. Miller DC, Wei JT, Dunn RL, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. *Urology* 2006;**68**(1):166-71
62. Monahan PO, Champion V, Rawl S, et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? *Qual Life Res* 2007;**16**(3):399-411
63. Namiki S, Satoh T, Baba S, et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. *Urology* 2006;**68**(6):1230-36
64. Namiki S, Kwan L, Kagawa-Singer M, et al. Distress and social dysfunction following prostate cancer treatment: a longitudinal cross-cultural comparison of Japanese and American men. *Prostate Cancer Prostatic Dis* 2009;**12**(1):67-71
65. Ohashi T, Yorozu A, Toya K, et al. Serial changes of international prostate symptom score following I-125 prostate brachytherapy. *Int J Clin Oncol* 2006;**11**(4):320-25

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
3 66. Pinkawa M, Fishedick K, Gagel B, et al. Association of neoadjuvant hormonal therapy
4 with adverse health-related quality of life after permanent iodine-125 brachytherapy for
5 localized prostate cancer. *Urology* 2006;**68**(1):104-09
6
7 67. Roach M, 3rd, Chinn DM, Holland J, et al. A pilot survey of sexual function and quality
8 of life following 3D conformal radiotherapy for clinically localized prostate cancer. *Int J*
9 *Radiat Oncol Biol Phys* 1996;**35**(5):869-74
10
11 68. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome
12 among prostate-cancer survivors. *N Engl J Med* 2008;**358**(12):1250-61
13
14 69. Schover LR, Fouladi RT, Warneke CL, et al. Defining sexual outcomes after treatment for
15 localized prostate carcinoma. *Cancer* 2002;**95**(8):1773-85
16
17 70. Soderdahl DW, Davis JW, Schellhammer PF, et al. Prospective longitudinal comparative
18 study of health-related quality of life in patients undergoing invasive treatments for
19 localized prostate cancer. *J Endourol* 2005;**19**(3):318-26
20
21 71. Speight JL, Elkin EP, Pasta DJ, et al. Longitudinal assessment of changes in sexual
22 function and bother in patients treated with external beam radiotherapy or brachytherapy,
23 with and without neoadjuvant androgen ablation: data from CaPSURE. *Int J Radiat*
24 *Oncol Biol Phys* 2004;**60**(4):1066-75
25
26 72. Stone NN, Marshall DT, Stone JJ, et al. Does neoadjuvant hormonal therapy improve
27 urinary function when given to men with large prostates undergoing prostate
28 brachytherapy? *J Urol* 2010;**183**(2):634-39
29
30 73. Trojan L, Harrer K, Schafer J, et al. [Complications and side effects of low dose rate
31 brachytherapy for the treatment of prostate cancer: data on a 13 year follow-up study
32 from Mannheim]. *Urologe A* 2007;**46**(11):1542-47
33
34 74. Tward JD, Lee CM, Pappas LM, et al. Survival of men with clinically localized prostate
35 cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of
36 age at diagnosis. *Cancer* 2006;**107**(10):2392-400
37
38 75. Valicenti RK, Bissondtte EA, Chen C, et al. Longitudinal comparison of sexual function
39 after 3-dimensional conformal radiation therapy or prostate brachytherapy. *J Urol*
40 2002;**168**(6):2499-504
41
42 76. Van de Poll-Franse LV, Sadetsky N, Kwan L, et al. Severity of cardiovascular disease and
43 health-related quality of life in men with prostate cancer: a longitudinal analysis from
44 CaPSURE. *Qual Life Res* 2008;**17**(6):845-55
45
46 77. Wyler SF, Engeler DS, Seelentag W, et al. Health-related quality of life after radical
47 prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. *Urol Int*
48 2009;**82**(1):17-23
49
50 78. Zagar TM, Stock RG, Cesaretti JA, et al. Assessment of postbrachytherapy sexual
51 function: a comparison of the IIEF-5 and the MSEFS. *Brachytherapy* 2007;**6**(1):26-33
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 Figure legends

4
5 Figure 1. Study flow

6 Abbreviation. PICO: population, intervention, comparator, outcome; PRO: patient-reported
7 outcomes; RCT: randomised controlled trial
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Table 1. Reasons for excluding PRO articles

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Bacon 2001 [29]	yes	yes	NO	-	-	-	-	-	No concurrent group
Ball 2006 [30]	yes	yes	NO	-	-	-	-	-	Cryotherapy
Befort 2005 [31]	yes	yes	yes	yes	NO	-	-	-	Low response
Bergman 2009 [32]	yes	yes	yes	yes	yes	yes	yes	NO	No appropriate test
Bergman 2010 [33]	yes	yes	yes	yes	NO	-	-	-	Low response
Brandeis 2000 [34]	yes	NO	-	-	-	-	-	-	29% LDR-BT + EBRT
Brown 2007 [35]	yes	NO	-	-	-	-	-	-	EBRT
Burnett 2007 [36]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Chaikin 1996 [37]	NO	-	-	-	-	-	-	-	Staging not reported
Chen 2009 [38]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Choo 2010 [39]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Clark 2003 [40]	yes	yes	yes	yes	NO	-	-	-	Low response
Downs 2003 [41]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Eton 2001 [42]	yes	yes	yes	yes	NO	-	-	-	Low response
Frank 2007 [43]	yes	yes	yes	yes	NO	-	-	-	Low response
Fulmer 2001 [44]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Gore 2009 [45]	yes	yes	yes	yes	NO	-	-	-	Low response
Guedea 2009 [46]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2008 [47]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2009 [48]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hervouet 2005 [49]	NO	-	-	-	-	-	-	-	≥20% T3-T4 in control groups
Hollenbeck 2002 [50]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Jo 2005 [51]	yes	NO	-	-	-	-	-	-	High-dose rate brachytherapy
Johnstone 2000 [52]	yes	NO	-	-	-	-	-	-	EBRT
Joly 1998 [53]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Kakehi 2007 [54]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Lev 2009 [55]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Lilleby 1999 [56]	yes	NO	-	-	-	-	-	-	EBRT
Litwin 2004 [57]	yes	yes	yes	yes	NO	-	-	-	Low response
Litwin 2007 [58]	yes	NO	-	-	-	-	-	-	25% LDR-BT + EBRT
Mehta 2003 [59]	yes	yes	yes	NO	-	-	-	-	"Fear of cancer"

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Miller 2005 [60]	yes	NO	-	-	-	-	-	-	44% LDR-BT + EBRT
Miller 2006 [61]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Monahan 2007 [62]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2006 [63]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2009 [64]	yes	yes	yes	yes	NO	-	-	-	Low response
Ohashi 2006 [65]	yes	yes	yes	yes	NO	-	-	-	Low response
Pinkawa 2006 [66]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Roach 1996 [67]	yes	NO	-	-	-	-	-	-	EBRT, single-arm trial
Sanda 2008 [68]	yes	yes	yes	yes	NO	-	-	-	Low response
Schover 2002 [69]	yes	yes	yes	yes	NO	-	-	-	Low response
Soderdahl 2005 [70]	yes	yes	yes	yes	NO	-	-	-	Low response
Speight 2004 [71]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Stone 2010 [72]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Trojan 2007 [73]	yes	yes	yes	yes	NO	-	-	-	Low response
Tward 2006 [74]	yes	yes	yes	NO	-	-	-	-	Mortality differs [§]
Valicenti 2002 [75]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Van de Poll-F 2008 [76]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Wyler 2009 [77]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Zagar 2007 [78]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
"NO" counts	2	13	4	2	19	3	6	1	Total: 50 studies
PICO not met: 21					High risk of bias: 29				

-: not appropriate

*Mehta 2003: no appropriate endpoint

[†]Pinkawa 2006; Stone 2010: neoadjuvant hormonal therapy

[§]Tward 2006: non-disease-related mortality differs greatly

Abbreviations: C: comparison of interest is radical prostatectomy, external beam radiotherapy, or no primary therapy; EBRT: external beam radiotherapy; I: intervention of interest is low-dose rate brachytherapy as monotherapy; LDR-BT: permanent interstitial low-dose rate brachytherapy; O: outcome of interest is function, bother, or generic health-related quality of life; P: patients with localized prostate cancer; PRO: patient-reported outcomes

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3
4 Failure to address potential bias in nonrandomized controlled clinical trials may cause lack of
5
6 evidence on patient-reported outcomes – a method study
7

8
9 Frank Peinemann,^{1,*} Alexander Michael Labeit,² Christian Thielscher,³ Michael Pinkawa,⁴

10
11 ¹Children's Hospital, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany

12 ²Outcomes Research Center, University of Illinois, One Illini Drive, Peoria, IL 61656, USA

13 ³FOM University of Applied Science for Economics & Management, Leimkugelstr. 6, 45141
14
15 Essen, Germany

16
17 ⁴Department of Radiotherapy, University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany

18
19
20
21 FP: pubmedprjournal@gmail.com

22
23 AML: alabeit.publications@gmail.com

24
25 CT: christian.thielscher@fom.de

26
27 MP: mpinkawa@ukaachen.de

28
29
30
31
32
33 *Corresponding author: Frank Peinemann, M.D., M.Sc., Children's Hospital, University of
34 Cologne, Kerpener Str. 62, 50937 Cologne, Germany; e-mail: pubmedprjournal@gmail.com.
35
36 Phone: +49-176-31130745.
37

38
39
40 Word count, excluding title page, abstract, references, figures and tables: 6102
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Abstract

Objectives: We conducted a workup of a previously published systematic review and aimed to analyse why most of the identified nonrandomized controlled clinical trials with patient-reported outcomes did not match a set of basic quality criteria.

Setting: There were no limits on the level of care and the geographical location.

Participants: The review evaluated permanent interstitial low-dose rate brachytherapy in patients with localized prostate cancer and compared that intervention to alternative procedures such as external beam radiotherapy, radical prostatectomy, and no primary therapy.

Primary outcome measure: Fulfilment of basic inclusion criteria according to a PICO framework and accomplishment of requirements to contain superimposed risk of bias.

Results: We found that 21 of 50 excluded nonrandomized controlled trials did not meet PICO inclusion criteria. The rest of 29 of 50 studies lacked quality of reporting. The resulting flaws included attrition bias due to loss of follow-up, lack of reporting baseline data, potential confounding due to unadjusted data and lack of statistical comparison between groups.

Conclusions: With respect to the reporting of patient-reported outcomes, active efforts are required to improve the quality of reporting in nonrandomized controlled trials concerning permanent interstitial low-dose rate brachytherapy in patients with localized prostate cancer.

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Key words: systematic review, patient-reported outcome, risk of bias

Strengths and limitations of this study

- We conducted a comprehensive literature search and strictly adhered to the projected methodology.
- We identified a lack of quality in nonrandomized controlled clinical trials reporting patient-reported outcomes, analysed the cause, and suggested possible improvements in designing studies in the future.
- The analysis is confined to a single disease and a specific treatment and conclusions drawn from its results may not be generalizable to other diseases and treatments.
- The limits for the inclusion of studies are arbitrarily set.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Abbreviation	Term
CCT	Nonrandomized controlled clinical trial
CONSORT	Consolidated standards of reporting trials
EBRT	External beam radiotherapy
EMBASE	Excerpta medica database
LDR-BT	Permanent interstitial low-dose rate brachytherapy
MEDLINE	Medical literature analysis and retrieval system online
PICO (TS-SD)	Participants, intervention, comparator, outcome (timing, setting, study design)
PRO	Patient-reported outcome
RCT	Randomized controlled trial
STROBE	Strengthening the reporting of observational studies in epidemiology
TNM	Tumor-Node-Metastasis

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 3 **Introduction**

4
5
6
7 The present paper reports a workup of a previously published systematic review [1]. It may be
8
9 regarded as a methodological supplement adding information on a subset of excluded studies.
10
11 We have compared permanent interstitial low-dose rate brachytherapy, with radical
12
13 prostatectomy, external beam radiotherapy, and 'no primary therapy' in patients with localized
14
15 prostate cancer categorized T1 to T2. We used the term 'no primary therapy' to accommodate
16
17 different types of observation including active surveillance, watchful waiting, and observing
18
19 without a distinctive management. As a result, we included one randomized controlled trial
20
21 (RCT) and 30 nonrandomized controlled clinical trials (CCT). The primary outcome was
22
23 overall survival. The secondary outcomes were clinically defined disease-free survival,
24
25 biochemical recurrence-free survival, physician-reported severe adverse events, and patient-
26
27 reported outcomes such as function and bother scores as well as generic and disease-related
28
29 health-related quality of life. We concluded that the current evidence is insufficient to allow a
30
31 definitive conclusion about overall survival. Radical prostatectomy and external beam
32
33 radiotherapy can severely affect the structural integrity of neighboring organs and their
34
35 functions and can cause considerable long-term impairment of health-related quality of life. In
36
37 a view of expecting similar survival but a tremendous difference of adverse events between
38
39 treatment alternatives, valid data on health-related quality of life could tip the balance. At
40
41 least, we assume that shared-decision making and consideration of patients' preferences in
42
43 searching for the best individual treatment would rely on information on health-related quality
44
45 of life data. Of the 30 included nonrandomized studies, 13 studies reported patient-reported
46
47 outcomes (PROs), that is, only the patients provided the information [2]. During the study
48
49 selection process, we experienced that we excluded another 50 nonrandomized PRO studies.
50
51 We found it a pity that we could not use the many data. We had the impression that a
52
53 considerable number of studies were excluded because of lack in reporting quality. Therefore,
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 we wanted to summarize the reasons for excluding those PRO studies and make aware that
4
5 authors of PRO studies should meet some basic requirements for reporting of comparative
6
7 PRO data to achieve higher acceptance in the scientific community. The importance of
8
9 reporting PRO has been addressed by the Consolidated Standards of Reporting Trials
10
11 (CONSORT) group [3] that recently has published a PRO extension to their acclaimed
12
13 previous statement [4]. It may be wise to build a PRO extension to the STrengthening the
14
15 Reporting of OBServational studies in Epidemiology (STROBE) statement [5] that addresses
16
17 specific issues of observational studies.
18
19

20
21 The first aim of this study was to assess whether the excluded studies met the basic inclusion
22
23 criteria using the PICO framework. The second aim of this study was whether the excluded
24
25 studies met requirements to contain high risk of bias.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 3 **Materials and Methods**

4 5 6 **Study inclusion criteria**

7
8
9
10 We defined the inclusion criteria according to the PICO framework that should include four
11 essential constituents, that is, the type of participants (P), intervention (I), comparator (C), and
12 outcome (O) [6]. The four PICO items can be supplemented by timing (T) and setting (S), two
13 other important features of a systematic review, to create the so-called PICOTS typology [7].
14
15 A further extension embraces the study design (SD) to complete all major items of a search
16 strategy (PICOTS-SD) [8].
17
18
19
20
21
22

23 24 *Population*

25
26
27 Initial and present publication: Localized prostate cancer is defined by the categories T1 to T2
28 of the Tumor-Node-Metastasis (TNM) staging system [9] if combined with an absence of
29 both regional lymph node metastasis and distant metastasis.
30
31
32

33 34 35 *Intervention*

36
37
38 Initial and present publication: Brachytherapy [10] is short-distance radiotherapy placing
39 radiation sources with different duration and rates of dose delivery in or near tumors [11].
40
41 Permanent interstitial low-dose rate brachytherapy means implanting of low-energy
42 radioactive sources emitting radiation, which are contained in titanium pellets of the size of
43 rice grains called seeds [12].
44
45
46
47
48

49 50 51 *Comparator*

52
53
54 Initial and present publication: The European Association of Urology suggested 3 different
55 treatment concepts for localized prostate cancer in addition to permanent interstitial low-dose
56 rate brachytherapy [10]: Radical prostatectomy, external beam radiotherapy, and different
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 types of observation including active surveillance, watchful waiting, and observing without a
3
4 distinctive management.
5
6

7
8 *Outcome*
9

10
11 Initial publication: Overall survival, cancer-specific survival, disease-free survival,
12 biochemical recurrence-free survival, severe adverse events, and patient-reported outcomes.
13
14 Patient-reported outcomes comprised function and bother scores as well as generic and
15
16 disease-related health-related quality of life.
17
18

19
20
21 Present publication: Fulfilment of basic inclusion criteria according to a PICO framework by
22
23 the excluded CCT. Accomplishment of requirements to contain superimposed risk of bias in
24
25 addition to the high risk of bias caused by the lack of randomization framework by the
26
27 excluded CCT.
28
29

30
31 *Timing*
32

33
34 Initial and present publication: We did not set limits on the length of the observation period.
35
36

37
38 *Setting*
39

40
41 Initial and present publication: We did not set limits on the setting such as type of country,
42
43 year of recruitment, or level of health care.
44
45

46
47 *Study design*
48

49
50 Initial publication: We included RCT and CCT evaluating permanent interstitial low-dose rate
51
52 brachytherapy as monotherapy in patients with localized prostate cancer. The proportion of
53
54 relevant patients was required to be at least 80% of the study population and the response rate
55
56 of questionnaires was expected to be at least 70%. For CCT to be included, comparable base-
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 line characteristics between treatment groups or adjustment for imbalances of these data were
4
5 required. Limits on year of publication or language were not applied.
6
7

8 Present publication: We included specifically the CCT that were excluded in the initial
9
10 publication.
11

12 13 **Search strategy**

14
15
16 The search strategy was reported previously [1].
17
18
19

20 **Study selection**

21
22 In the present study, we selected only those 50 nonrandomized studies on PRO that were ex-
23
24 cluded from the evaluation in the initial publication. In the study selection process, two re-
25
26 viewers independently judged whether a study was included or excluded. Differences were
27
28 resolved by discussion without the need for a third opinion.
29
30
31

32 **Data collection and analysis**

33
34 The reasons for exclusion were extracted independently by two reviewers. We sought for the
35
36 following data: the inclusion criteria using the PICO framework, the proportion of response of
37
38 participants to questionnaires, which was required to be at least 70%, the reporting of separate
39
40 baseline characteristics for each treatment group, the reporting of comparable baseline charac-
41
42 teristics or adjustment for imbalances of these data such as the use of a Cox proportional haz-
43
44 ard model, and the reporting of statistics comparing treatment groups. Sufficient comparabil-
45
46 ity was defined as a difference between baseline values that were not statistically significant.
47
48 If a statistical test was not reported, we assumed two comparable values if the greater of the
49
50 two values was less than 10% above the smaller one. We also required that authors reported
51
52 effect measures and statistics testing the difference between treatment groups, for example, p-
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 values or effect measures including 95% confidence intervals. Reporting of within group
3 comparisons or before-and-after analyses was not deemed sufficient for inclusion. We did not
4 apply a principal summary measure as we aimed at synthesize the information in a qualitative
5 way.
6
7
8
9
10

11 **Assessment of risk of bias and quality of reporting**

12
13 Two reviewers independently assessed the quality of reporting of CCT according to the crite-
14 ria specified in the previous paragraph. We did not specifically assess the risk of bias because
15 we decided to exclude all papers with regard to a lack of reporting essential data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Results

Of a total of 462 full-text articles assessed for eligibility in the previously published systematic review, 31 studies were included and 431 studies were excluded. Among the 431 excluded articles, we identified 50 nonrandomised studies that were reporting on PRO (Figure 1). We evaluated the reasons for exclusion of those 50 studies and documented the results in Table 1.

~~We documented the reasons for exclusion of all 50 nonrandomized studies that were identified as studies reporting on PRO (Table 1).~~ In 42% (21 of 50) studies, simply the essential PICO framework was not met. In the majority of 58% (29 of 50) studies, the predefined requirement to apply measures to contain high risk of bias was not met. Of these 29 studies, 19 studies reported a proportion of patients responding to questionnaires of less than 70% or did not address this item. Baseline characteristics were not presented for treatment groups in 3 studies. In another 6 studies, baseline characteristics were not comparable between treatment groups or there was no confounder control in the analysis adjusting for important different factors such as mean age. The statistical comparison between treatment groups was deemed not appropriate in 1 study.

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 3 **Discussion**

4 5 6 **Main results**

7
8
9
10 In summary, we found that roughly 4 of 10 excluded PRO studies did not meet the essential
11 inclusion criteria using the PICO framework. This result is consistent with the problem of
12 information retrieval aiming at a high recall and ending up with a low precision. The papers
13 were obviously not relevant to the research question and we did not further examine the re-
14 porting quality. We also found that roughly 6 of 10 excluded PRO studies met the PICO
15 framework but did not provide predefined requirements to care sufficiently enough for a low
16 response of patients to questionnaires, for reporting baseline characteristics between treatment
17 groups, for adjusting differences in those baseline characteristics between treatment groups,
18 and to use appropriate statistics to compare the outcome between treatment groups.
19
20
21
22
23
24
25
26
27
28
29
30

31 **Quality of reporting of patient-reported outcomes**

32
33
34 We identified a lack of quality of reporting in many excluded CCT and we want to stress the
35 importance of considering a series of requirements while conducting a study on PRO. Other
36 authors have reported recently that, concerning disease-specific mortality or disease-free sur-
37 vival, available studies did not show significant differences between treatment groups. [13
38 14]. In view of unknown or small differences in survival measures, the results of patient-
39 reported outcomes studies could have a noticeable impact on medical decision making [15
40 16]. None of the 50 excluded studies reported a non-responder analysis, though it is known
41 that non-responders may have different attitudes than responders. Etter 1997 concluded that
42 low response rates may be associated with overestimating an effect and that the strength and
43 direction of a non-response bias may depend on the mechanism of non-response [17]. There-
44 fore, results may be confounded if the proportion of included data not available for analysis
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 such as data from non-responders or due to loss to follow-up is considerable. We believe that
3 a value of 30% or more can be denoted as considerable. Lowering this threshold, for example
4 a value of 30% or more can be denoted as considerable. Lowering this threshold, for example
5 to 20%, would have resulted in less included studies. However, others suggested that 20% or
6 more loss would be sufficient for a high risk of bias threatening the validity of results [18].
7 Concerning questionnaires, we recommend taking measures that are known to improve re-
8 sponse rates [19 20]. Edwards 2009 conducted a systematic review to identify effective strat-
9 egies to increase the response to postal and electronic questionnaires [21]. The authors found
10 several strategies to increase the response, for example, pre-notification, follow-up contact,
11 shorter questionnaires, mentioning an obligation to respond, university sponsorship, non-
12 monetary incentives, a statement that others had responded, an offer of survey results, giving
13 a deadline. We did not use a strict algorithm to differentiate between comparable and not
14 comparable baseline values between treatment groups. A statistically significant difference
15 was judged as not comparable. Not significant differences were also regarded as not compa-
16 rable if the difference was at least 10% of the lower of two values. Using this approach we
17 tried to reduce subjective decisions. We are not aware of published strict algorithms in this
18 matter.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **High risk of bias inherent in nonrandomized controlled trials**

39
40
41
42 In the view of including only 1 RCT, the initial publication was based almost exclusively on
43 CCT. However, the lack of randomization poses a very large challenge on the authors that are
44 advised to deal with essential problems such as selection bias and confounding. Otherwise,
45 the findings may not be valid and of limited usefulness and the many efforts may be in vain.
46 We want to stress that the nonrandomized design is associated with a high risk of bias because
47 known and unknown characteristics may be distributed unequally between groups [22].
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 of results with respect to different baseline values, and confounder control can limit additional
4
5 bias. For example, Ioannidis 2001 [23] reported that discrepancies between RCT and CCT
6
7 were less common when only CCT with a prospective design were considered. The Cochrane
8
9 Collaboration offers a guide for inclusion of nonrandomized studies [24] and it has developed
10
11 a tool for assessing the risk of bias in both RCT and CCT [25]. Guidelines for reporting ob-
12
13 servational studies have been published to improve their quality [5]. Cox regression analysis,
14
15 propensity-score-based analysis, and instrumental variable analysis are methods that have
16
17 been used for correction of confounding bias in non-randomized studies [26]. Different values
18
19 of various outcome measures between groups may be simply caused by different baseline data
20
21 in lieu of absent significant treatment effects. We accepted any type of method adjusting or
22
23 stratifying for one or more known differences in baseline characteristics. Nevertheless, it
24
25 should be kept in mind that methods of adjustment do not guarantee removal of bias and that
26
27 residual confounding may remain high [22]. Concerning the non-randomized design, we
28
29 strongly recommend the use of methods for adjusting the results for confounders to aim for a
30
31 less biased estimation of the treatment effect [27] and the adoption of guidelines for the re-
32
33 porting of observational studies [5].
34
35
36
37
38

39 **Strengths and limitations**

40
41
42 The strengths of the present study are a comprehensive literature search, strict adherence to
43
44 the projected methodology, the identification of lack of quality in PRO studies and addressing
45
46 the specific problems of PRO studies. We should consider some limitations: The study is con-
47
48 fined to a single disease and conclusions drawn from its results may not be generalizable to
49
50 other diseases. The arbitrary limits set for inclusion of studies are responsible for the extent of
51
52 excluded studies. These limits may be questioned by other investigators. During re-evaluation
53
54 of study quality, we found that one study fulfilled all criteria, although, this study was exclud-
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 ed in previous reports [28]. The minimum follow-up of 70% for inclusion was set arbitrarily
3 and others might find this threshold too low. We did not endorse the recently published re-
4 porting of PRO in randomized trials, an extension of the CONSORT statement [4]. All in-
5 cluded studies in the present review are nonrandomized. We think that the lack of randomiza-
6 tion is the prevailing issue. We did not endorse the CONSORT PRO extension for another
7 reason. The included studies were published many years before this extension was published.
8 There might be a need to develop an extension of the STROBE statement [5] aiming to im-
9 prove the reporting of PRO in nonrandomized studies. This extension could emphasize the
10 specific challenges of reporting PRO with respect to lack of randomization.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

Conclusions

We found that a considerable number of non-randomized controlled reporting patient-reported outcomes were excluded from a systematic review because of a lack of predefined reporting requirements. The assumed overall risk of bias was regarded too high to consider the data of these studies for inclusion in the systematic review. With respect to the reporting of patient-reported outcomes, active efforts are required to improve the quality of reporting in nonrandomized controlled trials and to increase the number of randomized controlled trials.

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2 **Acknowledgements**

3
4
5
6
7 Acknowledgements: The authors declare that they have no competing interests. Parts of the
8
9 study have been presented at 19th Cochrane Colloquium 19 to 22 October 2011 in Madrid,
10
11 Spain. No funding bodies had any role in study design, data collection and analysis, decision
12
13 to publish, or preparation of the manuscript.

14
15
16
17 Funding: This research received no specific grant from any funding agency in the public,
18
19 commercial or not-for-profit sectors. The University of Cologne provided fulltexts. The fun-
20
21 ders had no role in study design, data collection and analysis, decision to publish, or prepara-
22
23 tion of the manuscript.

24
25
26 Competing interests: None declared

27
28
29
30 Author contribution: Conceived and designed the experiments: FP. Performed the experi-
31
32 ments: FP. Analyzed the data: FP MP. Wrote the manuscript: FP AML CT MP.

33
34
35 Reporting guidelines: PRISMA checklist is attached

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

References

1. Peinemann F, Grouven U, Bartel C, et al. Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer – a systematic review of randomized and non-randomized controlled clinical trials. *Eur Urol* 2011;**60**(5):881-93
2. Patrick D, Guyatt GH, Acquadro C. Chapter 17: Patient-reported outcomes. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane Collaboration, 2011.
3. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010;**7**(3):e1000251
4. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 2013;**309**(8):814-22
5. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007;**4**(10):e296
6. O'Connor D, Green S, Higgins JPT. Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane Collaboration, 2011.
7. *Methods Guide for Medical Test Reviews*. AHRQ Publication No. 12-EC017. Rockville: Agency for Healthcare Research and Quality, 2012.
8. White CM, Ip S, McPheeters M, et al. Using existing systematic reviews to replace de novo processes in conducting Comparative Effectiveness Reviews. *Methods Guide for Comparative Effectiveness Reviews*. Rockville: Agency for Healthcare Research and Quality, 2009.
9. Ebele JN, Sauter G, Epstein JI, et al. *Pathology and genetics of tumours of the urinary system and male genital organs*. Lyon: IARC Press, 2004.
10. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. Arnhem: European Association of Urology, 2011.
11. Prostate cancer. Guideline for the management of clinically localized prostate cancer: 2007 update. Linthicum: American Urological Association, 2007.
12. Nath R. Overview of brachytherapy physics. In: Thomadsen BR, Rivard MR, Butler W, eds. *Brachytherapy physics*. Second ed. Madison: Medical Physics Publishing, 2005.
13. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. *Ann Intern Med* 2008;**148**(6):435-48

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
- 3 14. Koukourakis G, Kelekis N, Armonis V, et al. Brachytherapy for prostate cancer: a
4 systematic review. *Adv Urol* 2009;327945
- 5
- 6 15. Rosenthal SA, Bittner NH, Beyer DC, et al. American Society for Radiation Oncology
7 (ASTRO) and American College of Radiology (ACR) practice guideline for the
8 transperineal permanent brachytherapy of prostate cancer. *Int J Radiat Oncol Biol Phys*
9 2011;**79**(2):335-41
- 10
- 11 16. Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of health-related quality of
12 life 5 years after SPIRIT (Surgical Prostatectomy [RP] versus Interstitial Radiation [BT]
13 Intervention trial ACOSOG Z0070). *Int J Radiat Oncol Biol Phys* 2010;**78**(3 Suppl
14 1):S76
- 15
- 16
- 17 17. Etter JF, Perneger TV. Analysis of non-response bias in a mailed health survey. *J Clin*
18 *Epidemiol* 1997;**50**(10):1123-8
- 19
- 20 18. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the
21 lost and wayward. *Lancet* 2002;**359**(9308):781-5
- 22
- 23 19. Smeeth L, Fletcher AE. Improving the response rates to questionnaires. *BMJ*
24 2002;**324**(7347):1168-9
- 25
- 26 20. Brealey SD, Atwell C, Bryan S, et al. Improving response rates using a monetary
27 incentive for patient completion of questionnaires: an observational study. *BMC Med*
28 *Res Methodol* 2007;**7**:12
- 29
- 30 21. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and
31 electronic questionnaires. *Cochrane Database Syst Rev* 2009(3):MR000008
- 32
- 33 22. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies.
34 *Health Technol Assess* 2003;**7**(27):iii-x, 1-173
- 35
- 36 23. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in
37 randomized and nonrandomized studies. *JAMA : the journal of the American Medical*
38 *Association* 2001;**286**(7):821-30
- 39
- 40 24. Reeves BC, Deeks JJ, Higgins JPT, et al. Chapter 13: Including non-randomized studies.
41 In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of*
42 *Interventions* Version 510 [updated March 2011]. Chichester: The Cochrane
43 *Collaboration*, 2011.
- 44
- 45 25. Higgins JPT, Altman DG, Sterne JAC. Chapter 8 Assessing risk of bias in included
46 studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of*
47 *Interventions* Version 510 [updated March 2011]. Oxford: The Cochrane Collaboration,
48 2011.
- 49
- 50 26. Schmoor C, Gall C, Stampf S, et al. Correction of confounding bias in non-randomized
51 studies by appropriate weighting. *Biom J* 2011;**53**(2):369-87
- 52
- 53 27. Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative
54 effectiveness research: approaches to mitigate bias and confounding in the design of
55 nonrandomized studies of treatment effects using secondary data sources: the
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. *Value Health* 2009;**12**(8):1053-61

28. Pinkawa M, Asadpour B, Piroth MD, et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer: a matched-pair comparison. *Radiother Oncol* 2009;**91**(2):225-31
29. Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. *J Urol* 2001;**166**(5):1804-10
30. Ball AJ, Gambill B, Fabrizio MD, et al. Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. *J Endourol* 2006;**20**(10):723-31
31. Befort CA, Zelefsky MJ, Scardino PT, et al. A measure of health-related quality of life among patients with localized prostate cancer: Results from ongoing scale development. *Clinical Prostate Cancer* 2005;**4**(2):100-08
32. Bergman J, Gore JL, Penson DF, et al. Erectile aid use by men treated for localized prostate cancer. *J Urol* 2009;**182**(2):649-54
33. Bergman J, Kwan L, Litwin MS. Improving decisions for men with prostate cancer: translational outcomes research. *J Urol* 2010;**183**(6):2186-92
34. Brandeis JM, Litwin MS, Burnison CM, et al. Quality of life outcomes after brachytherapy for early stage prostate cancer. *J Urol* 2000;**163**(3):851-57
35. Brown MW, Brooks JP, Albert PS, et al. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. *Prostate Cancer Prostatic Dis* 2007;**10**(2):189-93
36. Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. *J Urol* 2007;**178**(2):597-601
37. Chaikin DC, Broderick GA, Malloy TR, et al. Erectile dysfunction following minimally invasive treatments for prostate cancer. *Urology* 1996;**48**(1):100-04
38. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. *J Clin Oncol* 2009;**27**(24):3916-22
39. Choo R, Long J, Gray R, et al. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. *Support Care Cancer* 2010;**18**(6):715-22
40. Clark JA, Inui TS, Silliman RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. *J Clin Oncol* 2003;**21**(20):3777-84

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
- 3 41. Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients
4 treated with interstitial prostate brachytherapy for localized prostate cancer--data from
5 CaPSURE. *J Urol* 2003;**170**(5):1822-7
- 6
- 7 42. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate
8 carcinoma: an examination of treatment-related, demographic, and psychosocial factors.
9 *Cancer* 2001;**92**(6):1451-9
- 10
- 11 43. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical
12 prostatectomy, high dose external beam radiation therapy and brachytherapy iodine
13 implantation as monotherapies for localized prostate cancer. *J Urol* 2007;**177**(6):2151-56
- 14
- 15 44. Fulmer BR, Bissonette EA, Petroni GR, et al. Prospective assessment of voiding and
16 sexual function after treatment for localized prostate carcinoma: comparison of radical
17 prostatectomy to hormonobrachytherapy with and without external beam radiotherapy.
18 *Cancer* 2001;**91**(11):2046-55
- 19
- 20 45. Gore JL, Kwan L, Lee SP, et al. Survivorship beyond convalescence: 48-month quality-
21 of-life outcomes after treatment for localized prostate cancer. *J Natl Cancer Inst*
22 2009;**101**(12):888-92
- 23
- 24 46. Guedea F, Ferrer M, Pera J, et al. Quality of life two years after radical prostatectomy,
25 prostate brachytherapy or external beam radiotherapy for clinically localised prostate
26 cancer: the Catalan Institute of Oncology/Bellvitge Hospital experience. *Clin Transl*
27 *Oncol* 2009;**11**(7):470-78
- 28
- 29 47. Hashine K, Kusuhara Y, Miura N, et al. A prospective longitudinal study comparing a
30 radical retropubic prostatectomy and permanent prostate brachytherapy regarding the
31 health-related quality of life for localized prostate cancer. *Jpn J Clin Oncol*
32 2008;**38**(7):480-85
- 33
- 34 48. Hashine K, Kusuhara Y, Miura N, et al. Health-related quality of life using SF-8 and
35 EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent
36 prostate brachytherapy. *Jpn J Clin Oncol* 2009;**39**(8):502-08
- 37
- 38 49. Hervouet S, Savard J, Simard S, et al. Psychological functioning associated with prostate
39 cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy,
40 or surgery. *J Pain Symptom Manage* 2005;**30**(5):474-84
- 41
- 42 50. Hollenbeck BK, Dunn RL, Wei JT, et al. Neoadjuvant hormonal therapy and older age are
43 associated with adverse sexual health-related quality-of-life outcome after prostate
44 brachytherapy. *Urology* 2002;**59**(4):480-4
- 45
- 46 51. Jo Y, Junichi H, Tomohiro F, et al. Radical prostatectomy versus high-dose rate
47 brachytherapy for prostate cancer: effects on health-related quality of life. *BJU Int*
48 2005;**96**(1):43-47
- 49
- 50 52. Johnstone PA, Gray C, Powell CR. Quality of life in T1-3N0 prostate cancer patients
51 treated with radiation therapy with minimum 10-year follow-up. *Int J Radiat Oncol Biol*
52 *Phys* 2000;**46**(4):833-8
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT

53. Joly F, Brune D, Couette JE, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. *Ann Oncol* 1998;**9**:(7):751-57
54. Kakehi Y, Takegami M, Suzukamo Y, et al. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. *J Urol* 2007;**177**(5):1856-61
55. Lev EL, Eller LS, Gejerman G, et al. Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months. *Support Care Cancer* 2009;**17**(5):509-17
56. Lilleby W, Fossa SD, Waehre HR, et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. *Int J Radiat Oncol Biol Phys* 1999;**43**(4):735-43
57. Litwin MS, Sadetsky N, Pasta DJ, et al. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. *J Urol* 2004;**172**(2):515-9
58. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. *Cancer* 2007;**109**(11):2239-47
59. Mehta SS, Lubeck DP, Pasta DJ, et al. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. *J Urol* 2003;**170**:(5):1931-33
60. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *J Clin Oncol* 2005;**23**(12):2772-80
61. Miller DC, Wei JT, Dunn RL, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. *Urology* 2006;**68**(1):166-71
62. Monahan PO, Champion V, Rawl S, et al. What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? *Qual Life Res* 2007;**16**(3):399-411
63. Namiki S, Satoh T, Baba S, et al. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. *Urology* 2006;**68**(6):1230-36
64. Namiki S, Kwan L, Kagawa-Singer M, et al. Distress and social dysfunction following prostate cancer treatment: a longitudinal cross-cultural comparison of Japanese and American men. *Prostate Cancer Prostatic Dis* 2009;**12**(1):67-71
65. Ohashi T, Yoroza A, Toya K, et al. Serial changes of international prostate symptom score following I-125 prostate brachytherapy. *Int J Clin Oncol* 2006;**11**(4):320-25

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

- 2
3 66. Pinkawa M, Fishedick K, Gagel B, et al. Association of neoadjuvant hormonal therapy
4 with adverse health-related quality of life after permanent iodine-125 brachytherapy for
5 localized prostate cancer. *Urology* 2006;**68**(1):104-09
6
7 67. Roach M, 3rd, Chinn DM, Holland J, et al. A pilot survey of sexual function and quality
8 of life following 3D conformal radiotherapy for clinically localized prostate cancer. *Int J*
9 *Radiat Oncol Biol Phys* 1996;**35**(5):869-74
10
11 68. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome
12 among prostate-cancer survivors. *N Engl J Med* 2008;**358**(12):1250-61
13
14 69. Schover LR, Fouladi RT, Warneke CL, et al. Defining sexual outcomes after treatment for
15 localized prostate carcinoma. *Cancer* 2002;**95**(8):1773-85
16
17 70. Soderdahl DW, Davis JW, Schellhammer PF, et al. Prospective longitudinal comparative
18 study of health-related quality of life in patients undergoing invasive treatments for
19 localized prostate cancer. *J Endourol* 2005;**19**(3):318-26
20
21 71. Speight JL, Elkin EP, Pasta DJ, et al. Longitudinal assessment of changes in sexual
22 function and bother in patients treated with external beam radiotherapy or brachytherapy,
23 with and without neoadjuvant androgen ablation: data from CaPSURE. *Int J Radiat*
24 *Oncol Biol Phys* 2004;**60**(4):1066-75
25
26 72. Stone NN, Marshall DT, Stone JJ, et al. Does neoadjuvant hormonal therapy improve
27 urinary function when given to men with large prostates undergoing prostate
28 brachytherapy? *J Urol* 2010;**183**(2):634-39
29
30 73. Trojan L, Harrer K, Schafer J, et al. [Complications and side effects of low dose rate
31 brachytherapy for the treatment of prostate cancer: data on a 13 year follow-up study
32 from Mannheim]. *Urologe A* 2007;**46**(11):1542-47
33
34 74. Tward JD, Lee CM, Pappas LM, et al. Survival of men with clinically localized prostate
35 cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of
36 age at diagnosis. *Cancer* 2006;**107**(10):2392-400
37
38 75. Valicenti RK, Bissondtte EA, Chen C, et al. Longitudinal comparison of sexual function
39 after 3-dimensional conformal radiation therapy or prostate brachytherapy. *J Urol*
40 2002;**168**(6):2499-504
41
42 76. Van de Poll-Franse LV, Sadetsky N, Kwan L, et al. Severity of cardiovascular disease and
43 health-related quality of life in men with prostate cancer: a longitudinal analysis from
44 CaPSURE. *Qual Life Res* 2008;**17**(6):845-55
45
46 77. Wyler SF, Engeler DS, Seelentag W, et al. Health-related quality of life after radical
47 prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. *Urol Int*
48 2009;**82**(1):17-23
49
50 78. Zagar TM, Stock RG, Cesaretti JA, et al. Assessment of postbrachytherapy sexual
51 function: a comparison of the IIEF-5 and the MSEFS. *Brachytherapy* 2007;**6**(1):26-33
52
53
54
55
56
57
58
59
60

1 *Subject: bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

2
3 Figure legends

4
5 Figure 1. Study flow

6 Abbreviation. PICO: population, intervention, comparator, outcome; PRO: patient-reported
7 outcomes; RCT: randomised controlled trial
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Table 1. Reasons for excluding PRO articles

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Bacon 2001 [29]	yes	yes	NO	-	-	-	-	-	No concurrent group
Ball 2006 [30]	yes	yes	NO	-	-	-	-	-	Cryotherapy
Befort 2005 [31]	yes	yes	yes	yes	NO	-	-	-	Low response
Bergman 2009 [32]	yes	yes	yes	yes	yes	yes	yes	NO	No appropriate test
Bergman 2010 [33]	yes	yes	yes	yes	NO	-	-	-	Low response
Brandeis 2000 [34]	yes	NO	-	-	-	-	-	-	29% LDR-BT + EBRT
Brown 2007 [35]	yes	NO	-	-	-	-	-	-	EBRT
Burnett 2007 [36]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Chaikin 1996 [37]	NO	-	-	-	-	-	-	-	Staging not reported
Chen 2009 [38]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Choo 2010 [39]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Clark 2003 [40]	yes	yes	yes	yes	NO	-	-	-	Low response
Downs 2003 [41]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Eton 2001 [42]	yes	yes	yes	yes	NO	-	-	-	Low response
Frank 2007 [43]	yes	yes	yes	yes	NO	-	-	-	Low response
Fulmer 2001 [44]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Gore 2009 [45]	yes	yes	yes	yes	NO	-	-	-	Low response
Guedea 2009 [46]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2008 [47]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hashine 2009 [48]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Hervouet 2005 [49]	NO	-	-	-	-	-	-	-	≥20% T3-T4 in control groups
Hollenbeck 2002 [50]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Jo 2005 [51]	yes	NO	-	-	-	-	-	-	High-dose rate brachytherapy
Johnstone 2000 [52]	yes	NO	-	-	-	-	-	-	EBRT
Joly 1998 [53]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Kakehi 2007 [54]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Lev 2009 [55]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Lilleby 1999 [56]	yes	NO	-	-	-	-	-	-	EBRT
Litwin 2004 [57]	yes	yes	yes	yes	NO	-	-	-	Low response
Litwin 2007 [58]	yes	NO	-	-	-	-	-	-	25% LDR-BT + EBRT
Mehta 2003 [59]	yes	yes	yes	NO	-	-	-	-	"Fear of cancer"

Subject: *bmjopen-2013-004720.R1.: Failure to address potential bias in CCT*

Nonrandomized studies	Inclusion criteria				Requirements to contain high risk of bias				Comments
	P	I	C	O	Response ≥70%	Baseline each group	Baseline comparable/ or adjusted	Statistical comparison between groups	
Miller 2005 [60]	yes	NO	-	-	-	-	-	-	44% LDR-BT + EBRT
Miller 2006 [61]	yes	yes	yes	yes	yes	NO	-	-	Baseline not reported
Monahan 2007 [62]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2006 [63]	yes	yes	yes	yes	NO	-	-	-	Low response
Namiki 2009 [64]	yes	yes	yes	yes	NO	-	-	-	Low response
Ohashi 2006 [65]	yes	yes	yes	yes	NO	-	-	-	Low response
Pinkawa 2006 [66]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Roach 1996 [67]	yes	NO	-	-	-	-	-	-	EBRT, single-arm trial
Sanda 2008 [68]	yes	yes	yes	yes	NO	-	-	-	Low response
Schover 2002 [69]	yes	yes	yes	yes	NO	-	-	-	Low response
Soderdahl 2005 [70]	yes	yes	yes	yes	NO	-	-	-	Low response
Speight 2004 [71]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Stone 2010 [72]	yes	yes	NO	-	-	-	-	-	LDR-BT + hormones [†]
Trojan 2007 [73]	yes	yes	yes	yes	NO	-	-	-	Low response
Tward 2006 [74]	yes	yes	yes	NO	-	-	-	-	Mortality differs [§]
Valicenti 2002 [75]	yes	yes	yes	yes	NO	-	-	-	Response not reported
Van de Poll-F 2008 [76]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
Wyler 2009 [77]	yes	yes	yes	yes	yes	yes	NO	-	No confounder control
Zagar 2007 [78]	yes	NO	-	-	-	-	-	-	LDR-BT + EBRT
"NO" counts	2	13	4	2	19	3	6	1	Total: 50 studies
	PICO not met: 21				High risk of bias: 29				


-: not appropriate

*Mehta 2003: no appropriate endpoint

[†]Pinkawa 2006; Stone 2010: neoadjuvant hormonal therapy

[§]Tward 2006: non-disease-related mortality differs greatly

Abbreviations: C: comparison of interest is radical prostatectomy, external beam radiotherapy, or no primary therapy; EBRT: external beam radiotherapy; I: intervention of interest is low-dose rate brachytherapy as monotherapy; LDR-BT: permanent interstitial low-dose rate brachytherapy; O: outcome of interest is function, bother, or generic health-related quality of life; P: patients with localized prostate cancer; PRO: patient-reported outcomes



Abbreviation. PICO: population, intervention, comparator, outcome; PRO: patient-reported outcomes; RCT: randomised controlled trial
170x235mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	7
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7-8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	figure 1
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	9
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9-10
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9-10
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	10
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12-15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14-15
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.